EVIDED ORTHOGONAL RIBOSOMES

Inventors: Jason Chin, Cambridge (GB); Kaishang Wang, Cambridge (GB); Heinz Neumann, Cambridge (GB)

Assignee: Medical Research Council, London (GB)

Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 109 days.

Appl. No.: 12/516,230
PCT Filed: Nov. 28, 2007
PCT No.: PCT/GB2007/004562
§ 371 (e)(1), (2), (4) Date: Dec. 15, 2009
PCT Pub. No.: WO2008/065398
PCT Pub. Date: Jun. 5, 2008

Prior Publication Data
US 2010/0105565 A1 Apr. 29, 2010

Related U.S. Application Data
Provisional application No. 60/939,906, filed on May 24, 2007.

Foreign Application Priority Data
Nov. 30, 2006 (GB) 0623974.3
May 25, 2007 (GB) 0710094.4

Int. Cl.
C10I 50/06 (2006.01)
A07H 21/02 (2006.01)
A61K 38/00 (2006.01)
C07K 4/00 (2006.01)

U.S. CL.
USPC 506/26; 536/23.1; 530/300

There is provided a method for evolving an orthogonal rRNA molecule, comprising the steps of: providing one or more libraries of mutant orthogonal rRNA molecules and introducing the libraries into cells such that the orthogonal rRNA is incorporated into ribosomes to provide orthogonal ribosomes; providing one or more orthogonal mRNA molecules which (i) are not translated by natural ribosomes, and (ii) comprise one or more orthogonal mRNA codons; assaying the translation of the orthogonal mRNA and selecting the orthogonal rRNA molecules which translate the orthogonal mRNA, wherein the assay in step (c) requires translation of one or more orthogonal mRNA codons in the orthogonal mRNA; and orthogonal ribosomes incorporating such rRNA molecules.
OTHER PUBLICATIONS

Engeland et al., Cell, 96:80-98 (1999).
Petry et al., Cell, 123:1255-1266 (2005).
Short et al., Biochemistry, 38:8008-8819 (1999).

* cited by examiner
FIG. 1

C

<table>
<thead>
<tr>
<th></th>
<th>520</th>
<th>530</th>
<th>540</th>
</tr>
</thead>
<tbody>
<tr>
<td>wt</td>
<td>AGCAGCCGCGGUAAAUACGAG</td>
<td>(SEQ ID NO:19)</td>
<td></td>
</tr>
<tr>
<td>529/35N7</td>
<td>AGCAGCCGCGNNNNNNNCGGAG</td>
<td>(SEQ ID NO:20)</td>
<td></td>
</tr>
<tr>
<td>529/35N5</td>
<td>AGCAGCCGCGNNNNNCCGGAG</td>
<td>(SEQ ID NO:21)</td>
<td></td>
</tr>
<tr>
<td>529/35N6</td>
<td>AGCAGCCGCGNNNNNCCGGAG</td>
<td>(SEQ ID NO:22)</td>
<td></td>
</tr>
<tr>
<td>529/35N8</td>
<td>AGCAGCCGCGNNNNNCCGGAG</td>
<td>(SEQ ID NO:23)</td>
<td></td>
</tr>
<tr>
<td>529/35N9</td>
<td>AGCAGCCGCGNNNNNCCGGAG</td>
<td>(SEQ ID NO:24)</td>
<td></td>
</tr>
</tbody>
</table>
FIG. 2
A

16S
LibN7

GG AG G (SEQ ID NO:61)

GG AG G (SEQ ID NO:62)

UAGA Decoding Selection

AGGA Decoding Selection

(SEQ ID NO:63)

(SEQ ID NO:64)

C CG C G G A A A C G G AG G

C CG C G G N A A A A A C G G AG G

B

<table>
<thead>
<tr>
<th>Ribosome</th>
<th>Sequence (529-531)</th>
<th>Repeats</th>
<th>IC50 (Cm mg/l)</th>
</tr>
</thead>
<tbody>
<tr>
<td>O-ribosome</td>
<td>GGAAUA</td>
<td>AGGA seln.</td>
<td>O-cat AGGA</td>
</tr>
<tr>
<td>ribo-X</td>
<td>GGGAAA</td>
<td>3</td>
<td>140  125</td>
</tr>
<tr>
<td>7-2</td>
<td>GGGAGA</td>
<td>1</td>
<td>140  90</td>
</tr>
<tr>
<td>7-10</td>
<td>GGGAAAA</td>
<td>4</td>
<td>140  30</td>
</tr>
<tr>
<td>7-5</td>
<td>GGUAAAA</td>
<td>2</td>
<td>140  ND</td>
</tr>
</tbody>
</table>

C

O-ribosome
Ribo-X
O-ribosome + tRNA (UCUA)
Ribo-X + tRNA (UCUA)

FIG. 3
<table>
<thead>
<tr>
<th></th>
<th>O-ribosome</th>
<th>25</th>
<th>15</th>
<th>10</th>
<th>10</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Ribo-X</td>
<td>125</td>
<td>120</td>
<td>40</td>
<td>15</td>
</tr>
<tr>
<td></td>
<td>Enhancement</td>
<td>5</td>
<td>6</td>
<td>4</td>
<td>1.5</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th>O-ribosome</th>
<th>10</th>
<th>80</th>
<th>80</th>
<th>15</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Ribo-X</td>
<td>25</td>
<td>140</td>
<td>80</td>
<td>100</td>
</tr>
<tr>
<td></td>
<td>Enhancement</td>
<td>2.5</td>
<td>1.7</td>
<td>1</td>
<td>8</td>
</tr>
</tbody>
</table>

FIG. 4
FIG. 5

| O-Ribosome | - | - | + | + | - | - | + | - |
| Ribo-X   | - | - | - | - | + | + | - | + |
| WT Ribosome | + | + | - | - | - | - | - | - |
| tRNA(UCUA) | - | + | - | - | + | + | - | - |
| O-cat (UAGA) | + | + | + | + | + | + | - | - |
| O-cat    | - | - | - | - | - | - | + | + |

FIG. 6

<table>
<thead>
<tr>
<th>Codon</th>
<th>4th base pair</th>
</tr>
</thead>
<tbody>
<tr>
<td>UAGU</td>
<td>U:U</td>
</tr>
<tr>
<td>UAGG</td>
<td>G:U</td>
</tr>
<tr>
<td>UAGC</td>
<td>C:U</td>
</tr>
<tr>
<td>UAGA</td>
<td>A:U</td>
</tr>
</tbody>
</table>

A

B

Ribosomal RNA (ribosome), tRNA (UCUA), O-cat (UAGA), O-cat (XXX) and their interactions are shown in the diagrams. The codon 4th base pairs are UAGU, UAGG, UAGC, and UAGA. The concentration of Cm (mg/l) is shown in the graphs.
FIG. 8
FIG. 9
**FIG. 10**

- **A**: Diagram showing the expression of GST-MBP at 71 kDa.
- **B**: Mass spectrometry analysis comparing Wt-ribosome, O-ribosome, and Ribo-X.
- **C**: Gel electrophoresis showing MBP and GST proteins.
- **D**: Bar graph depicting F-Luc activity relative to Wt-ribosome for UUU, AAU, AGA, and CAA codons.

Identity of codon 529 in F-Luc
FIG. 11
## Supplementary Table 1528/36 16S rDNA Libraries Construction

<table>
<thead>
<tr>
<th>Randomized Nucleotide</th>
<th>Combinations (4^n)</th>
<th>No. of clones for 99% coverage</th>
<th>Actual Library Size</th>
</tr>
</thead>
<tbody>
<tr>
<td>N5 5</td>
<td>(4^5 = 1,024)</td>
<td>4,716</td>
<td>(2.4 \times 10^6)</td>
</tr>
<tr>
<td>N6 6</td>
<td>(4^6 = 4,096)</td>
<td>18,862</td>
<td>(3.6 \times 10^5)</td>
</tr>
<tr>
<td>N7 7</td>
<td>(4^7 = 16,384)</td>
<td>75,448</td>
<td>(1.0 \times 10^5)</td>
</tr>
<tr>
<td>N8 8</td>
<td>(4^8 = 65,636)</td>
<td>301,793</td>
<td>(5.0 \times 10^4)</td>
</tr>
<tr>
<td>N9 9</td>
<td>(4^9 = 262,144)</td>
<td>1,207,173</td>
<td>(4.2 \times 10^4)</td>
</tr>
</tbody>
</table>

**FIG. 12**
## Supplementary Table 2: Primers Used

<table>
<thead>
<tr>
<th>Name</th>
<th>Sequence (5' → 3')</th>
<th>Purpose</th>
</tr>
</thead>
<tbody>
<tr>
<td>528/36N5f wd</td>
<td>GGAAAGGTCTCAGCAGCAGCGNCCNCCGAGGAGGT</td>
<td>528/36N5 library construction</td>
</tr>
<tr>
<td>528/36N6f wd</td>
<td>GGAAGGTTCTACGACCGCAGCGNCNCCGAGGAGG</td>
<td>528/36N6 library construction</td>
</tr>
<tr>
<td>528/36N7f wd</td>
<td>GGAAGGTTCTACGAGCGCAGCGNCNCCGAGGAGG</td>
<td>528/36N7 library construction</td>
</tr>
<tr>
<td>528/36N8f wd</td>
<td>GGAAGGTTCTACGAGCGCAGCGNCNCCGAGGAGG</td>
<td>528/36N8 library construction</td>
</tr>
<tr>
<td>528/36N9f wd</td>
<td>GGAAGGTTCTACGAGCGCAGCGNCNCCGAGGAGG</td>
<td>528/36N9 library construction</td>
</tr>
<tr>
<td>528/36revL</td>
<td>GAGTAGGTCTACTGTCGAGGAGGAGGAGGAGGAGG</td>
<td>528/36N5,6,7,8,9 libraries construction</td>
</tr>
<tr>
<td>1fSer2Fla</td>
<td>CACAAAGATATCCGCGTTCATTGAGGAGACAGTC</td>
<td>Ser² tRNA with mutated ASL, primer assembly</td>
</tr>
<tr>
<td></td>
<td>AAAATAAGTGGGCGCCACCATCAGATAATTTCT</td>
<td></td>
</tr>
<tr>
<td></td>
<td>CAACATAAAAAAAAAACTTTGTTGTAATACCTTGTAACG</td>
<td></td>
</tr>
<tr>
<td>2fSer2Fla</td>
<td>CTCAACATAAAAAAAAAACTTTGTTGTAATACCTTGTAACG</td>
<td>Ser² tRNA with mutated ASL, primer assembly</td>
</tr>
<tr>
<td></td>
<td>CTGAATACACGTGACCGCAGCCATATGAGAGAGATG</td>
<td></td>
</tr>
<tr>
<td></td>
<td>CCGGAGCGGGCTGAAAGGAC</td>
<td></td>
</tr>
<tr>
<td>3rSer2Fla</td>
<td>GTGCCGAGAGAGAGAGAGAGAGATGAACATCACCTCAGGTCAGGTTGAGATAGCAGGTTGAGTCCG</td>
<td>Ser² tRNA with mutated ASL, primer assembly</td>
</tr>
<tr>
<td></td>
<td>TTAGTGCACTCGGCTCGGAGGCTCCGTCCTCC</td>
<td></td>
</tr>
<tr>
<td>4rSer2Fla</td>
<td>CACAAATGATATCTTTTTTTTACTTGTTAGGTTGAGG</td>
<td>Ser² tRNA with mutated ASL, primer assembly</td>
</tr>
<tr>
<td></td>
<td>TAAAGGATCTGGCGAGCGCCGGGCGGCTAGGTTGGCGG</td>
<td></td>
</tr>
<tr>
<td></td>
<td>GAGAGAGAGAGAGGAGGAGGAGGAGGAGGAGGAGG</td>
<td></td>
</tr>
<tr>
<td>CATS103T AGAfw</td>
<td>CAGACTGAAACGGTTTGAATCAGCTTGGAGTGA</td>
<td>TAGA mutation at Ser 103</td>
</tr>
<tr>
<td></td>
<td>TACCAGCAGCTTCCC</td>
<td></td>
</tr>
<tr>
<td>CATS103T AGArv</td>
<td>TTCTGCACTCAGGATCTAAAAACGGTTCTCCAGCGCTTCG</td>
<td>TAGA mutation at Ser 103</td>
</tr>
<tr>
<td></td>
<td>TCATGGAAAAACGTTG</td>
<td></td>
</tr>
<tr>
<td>CATS146T AGAfw</td>
<td>AAATGTTTTTCTGGGACTGAGGCCACTCCTGAGG</td>
<td>TAGA mutation at Ser 146</td>
</tr>
<tr>
<td></td>
<td>GTTTTCACCCAGTTTTG</td>
<td></td>
</tr>
<tr>
<td>CATS146T AGArv</td>
<td>AAAACACAGTATCTGAGTCAGCCACAGGCCAGGTGAGG</td>
<td></td>
</tr>
</tbody>
</table>

FIG. 13
<table>
<thead>
<tr>
<th>AGArv</th>
<th>CTAATAAACCTTTTAG (SEQ ID NO:48)</th>
<th>Ser 146</th>
</tr>
</thead>
<tbody>
<tr>
<td>CATS103T AGfw</td>
<td>CAGACTGAAACGTTTAGTCGCTCTGGAGTGAAT ACCACGACGATTTCC (SEQ ID NO:49)</td>
<td>TAG mutation at Ser 103</td>
</tr>
<tr>
<td>CATS103T AGrv</td>
<td>TTCACCTCCAGAGCGACTAAAAACGTTTCAGTCTGCT CATGAAAACGGTG (SEQ ID NO:50)</td>
<td>TAG mutation at Ser 103</td>
</tr>
<tr>
<td>CATS146T AGfw</td>
<td>AATATGTITTTCTGCTAGGCGAATCCCTGGGTAG TTTACCCAGTTTTG (SEQ ID NO:51)</td>
<td>TAG mutation at Ser 146</td>
</tr>
<tr>
<td>CATS146T AGrv</td>
<td>CACCCAGGATTGGCCTAGACGAAAAAACATATTCTCAATAAAACCTTTTAG (SEQ ID NO:52)</td>
<td>TAG mutation at Ser 146</td>
</tr>
<tr>
<td>TRNAtagtf w</td>
<td>CTACTCGGTGTAGTATACCGGTCCGCCGTTACGCCGCTCGGCATCTCTCC (SEQ ID NO:53)</td>
<td>anti-UAGA Ser² tRNA with mutated ASL</td>
</tr>
<tr>
<td>TRNAtagtr v</td>
<td>TGAACCGACCGGTATAACTAACACCCGACGTTAGGGGCAACTCTACCACGGG (SEQ ID NO:54)</td>
<td>anti-UAGA Ser² tRNA with mutated ASL</td>
</tr>
</tbody>
</table>

FIG. 13 CONT'D
FIG. 14

<table>
<thead>
<tr>
<th></th>
<th>301</th>
<th>315</th>
</tr>
</thead>
<tbody>
<tr>
<td>O-cat aa 101-105</td>
<td>acg ttt tca tcg ctc</td>
<td>Thr Phe Ser Ser Leu</td>
</tr>
<tr>
<td>UAGA103</td>
<td>acg ttt uaga tcg ctc</td>
<td>Thr Phe Quad Ser Leu</td>
</tr>
<tr>
<td>UAG103</td>
<td>acg ttt uag agt ctc</td>
<td>Thr Phe Amb Ser Leu</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th>430</th>
<th>444</th>
</tr>
</thead>
<tbody>
<tr>
<td>O-cat aa 144-148</td>
<td>ttc gtc tca gcc aat</td>
<td>Phe Val Ser Ala Asn</td>
</tr>
<tr>
<td>UAGA146</td>
<td>ttc gtc uaga gcc aat</td>
<td>Phe Val Quad Ala Asn</td>
</tr>
</tbody>
</table>

FIG. 15
<table>
<thead>
<tr>
<th></th>
<th>gst</th>
<th>Linker</th>
<th>malE</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>ctg gtt ccc gct gga tcc ccc gga att cat cgt gac</td>
<td>ggg TAC ctc aaa atc GAA gaa ggt aaa ctg gta atc</td>
<td></td>
</tr>
<tr>
<td>L</td>
<td>V</td>
<td>P</td>
<td>R</td>
</tr>
<tr>
<td>G</td>
<td>S</td>
<td>P</td>
<td>G</td>
</tr>
<tr>
<td></td>
<td>I</td>
<td>H</td>
<td>R</td>
</tr>
<tr>
<td></td>
<td>D</td>
<td>G</td>
<td>Y</td>
</tr>
<tr>
<td></td>
<td>Y</td>
<td>L</td>
<td>K</td>
</tr>
<tr>
<td></td>
<td>I</td>
<td>E</td>
<td>E</td>
</tr>
<tr>
<td></td>
<td>G</td>
<td>K</td>
<td>L</td>
</tr>
<tr>
<td></td>
<td>V</td>
<td>I</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th>Thrombin</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

FIG. 16

![Graph](image)

FIG. 17

![Graph](image)
<table>
<thead>
<tr>
<th>Sample</th>
<th>wt-ribosome</th>
<th>Rib-X</th>
<th>BpaRS/trNA&lt;sub&gt;U&lt;/sub&gt;A</th>
<th>Bpa</th>
<th>wt-gst(UAG),maIE</th>
<th>O-gst(UAG),maIE</th>
</tr>
</thead>
<tbody>
<tr>
<td>wt-ribosome</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Rib-X</td>
<td>-</td>
<td>+</td>
<td>-</td>
<td>+</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>BpaRS/trNA&lt;sub&gt;U&lt;/sub&gt;A</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Bpa</td>
<td>-</td>
<td>-</td>
<td>+</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>wt-gst(UAG),maIE</td>
<td>0</td>
<td>1</td>
<td>1</td>
<td>2</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>O-gst(UAG),maIE</td>
<td>0</td>
<td>-</td>
<td>1</td>
<td>1</td>
<td>2</td>
<td>2</td>
</tr>
</tbody>
</table>

**FIG. 18**

**FIG. 19**
EVOlVED ORTHOGONAL RIBOSOMES

The present application is filed pursuant to 35 U.S.C. 371 as a U.S. National Phase application of International Patent Application No. PCT/GB07/04562, which was filed Nov. 28, 2007, claiming the benefit of priority to British Patent Application No. 6623973.3, which was filed on Nov. 30, 2006, U.S. Patent Application No. 60/939,906, which was filed on May 24, 2007, and British Patent Application No. 0710094-A, which was filed on May 25, 2007. The entire text of the aforementioned, PCT/GB07/04562 is incorporated herein by reference in its entirety.

The present invention relates to orthogonal ribosomes with enhanced translation efficiency for orthogonal RNA. In particular, the invention provides orthogonal ribosomes with enhanced translation efficiency for quadruplet and amber codons.

INTRODUCTION

We recently created orthogonal ribosome-mRNA pairs that operate in parallel with, but independent of, the cellular ribosome. The orthogonal mRNA contains a ribosome-binding site that does not direct translation by endogenous ribosomes but is efficiently translated by an orthogonal ribosome, which does not appreciably translate cellular mRNAs. In previous work we have explored the use of orthogonal ribosomes to create new modes of system-level translational regulation and to understand the relationship between ribosome structure and function.

The triplet nature of the genetic code is conserved across all known organisms. Rare exceptions to the correspondence between an mRNA triplet sequence and the amino acid encoded include frame shifts (+1, +2, –1, –2), hops, and read-through of stop signals. While many programmed changes of reading frame require upstream sequences in the mRNA that recruit additional translation factors or that interact with and prepare the translational machinery for a change of reading frame, +1 frame shift mutations that create quadruplet codons can be read, independent of upstream signals, by tRNAs with extended anticodon loops. The apparent simplicity and uniqueness of quadruplet codons as amino acid insertion signals has led to the use of extended anticodon tRNAs to encode the incorporation of unnatural amino acids, albeit with low efficiency, both in vitro and in vivo.

The mechanism of quadruplet decoding, the efficiency of quadruplet decoding, and the range of quadruplet codon/anticodon pairs accessible to the natural translational machinery have been investigated for over 35 years. Recently, Schultz and coworkers explored the scope of quadruplet codon-anticodon pairs that operate with the natural translational machinery by crossing a library of extended anticodon tRNA mutants, derived from tRNAsel, with a library of quadruplet codons. They discovered a group of extended anticodon tRNAs able to read their cognate quadruplet codons, including UAG, AGGA, and CCCU, in vivo. The in vivo efficiency of quadruplet decoding by extended anticodon tRNAs is poor (from less than 1% to about 20%)

It is clear that the efficiency of decoding quadruplet codons with extended anticodon tRNAs is limited by the natural ribosome, that has evolved to read a triplet code.

Evolving and engineering the natural ribosome is a challenge on several levels. First, the ribosome is massive: at 2.5 MDa and containing three large RNAs and 52 proteins, it is an order of magnitude larger than most macromolecules that have been engineered or evolved. Fortunately, structural biolog,y, biochemistry and mutagenesis have begun to provide insights into the molecular basis of ribosome function, and provide a molecular basis for targeted efforts to expand ribosome function. Second, the ribosome is essential, and highly conserved. Many mutations in ribosomal components are dominant negative, deleterious or lethal since they compromise the efficient and accurate synthesis of the proteome.

The genetic code of prokaryotic and eukaryotic organisms has been expanded to allow the in vivo, site-specific incorporation of over 20 designer unnatural amino acids in response to the amber stop codon. This synthetic genetic code expansion is accomplished by endowing organisms with evolved orthogonal aminoacyl-tRNA synthetases/tRNA\textsubscript{\textsc{am}}-\textsc{ula} pairs that direct the site-specific incorporation of an unnatural amino acid in response to an amber codon. The orthogonal aminoacyl-tRNA synthetase aminoacylates a cognate orthogonal tRNA, but no other cellular tRNAs, with an unnatural amino acid, and the orthogonal tRNA is a substrate for the orthogonal synthetase but is not substantially aminoacylated by any endogenous aminoacyl-tRNA synthetase.

Genetic code expansion in E. coli using evolved variants of the orthogonal Methanococcus jannaschii tyrosyl-tRNA synthetase/tRNA\textsubscript{\textsc{am}}-\textsc{ula} pair greatly increases unnatural amino acid-containing protein yield since, in contrast to methods that rely on the addition of stoichiometrically pre-aminoacylated suppressor tRNAs to cells or to in vitro translation reactions, the orthogonal tRNA\textsubscript{\textsc{am}}-\textsc{ula} is catalytically re-aminoacylated by its cognate aminoacyl-tRNA synthetase enzyme, thus aminoacylation need not limit translational efficiency.

While in vivo genetic code expansion is clearly a major advance, the efficiency of site-specific unnatural amino acid incorporation in E. coli via amber suppression is severely limited; Release factor-1 (RF-1) mediated peptide chain termination competes with tRNACua mediated chain elongation, and therefore 70-80% of polypeptide synthesis initiated on genes containing a single amber stop codon is terminated at that codon. This clearly limits (to ~20-30%) the efficiency with which proteins containing unnatural amino acids are synthesized from genes containing a single internal amber stop codon. Moreover, the efficiency of unnatural amino acid incorporation decreases drastically with increasing amber stop codons in a gene, such that less than one-tenth of protein synthesis initiated on a gene containing two amber codons typically reaches completion.

Many potential applications of unnatural amino acid mutagenesis, including the translational incorporation of amino acids corresponding to post-translational modifications present at multiple sites in proteins (eg: methylation, acetylation, phosphorylation), require more efficient methods of incorporation to make useful amounts of protein. Moreover, the introduction of biophysical probes and chemically precise perturbations into proteins in their native cellular context offers the exciting possibility of understanding and controlling cellular functions in ways not previously possible. However, the large amount of truncated protein produced in these experiments may provide a substantial perturbation to the system under study, confounding meaningful conclusions about the function of full-length unnatural amino acid-containing protein in the cell.

Unnatural amino acid incorporation in vitro translation reactions can be increased by using S30 extracts containing a thermally inactivated mutant of RF-1. Unfortunately, though temperature sensitive mutants of RF-1 allow transient increases in global amber suppression in vivo, RF-1 knockouts are lethal, and are therefore not a viable option for stably and specifically increasing the efficiency of unnatural amino acid incorporation in E. coli. Increases in tRNACua gene
copy number and a transition from minimal to rich media have provided some improvement in the yield of proteins incorporating an unnatural amino acid in *E. coli*, but the efficiency of unnatural amino acid incorporation (defined as the ratio of full length protein to truncated protein) is still only 20-30%. Additional improvements possible through a further increase in tRNA copy number are problematic for several reasons. First, this strategy increases the extent to which natural aminosyrl-tRNA synthetases aminosylate the orthogonal tRNA, potentially leading to natural amino acid incorporation in response to the amber, codon. Second, the plasmid encoded tRNACUA gene repeats typically used to achieve increases in tRNA copy number are prone to recombination-mediated inactivation. Third, the strategy indiscriminately increases suppression of all amber codons in the cell and therefore enhances the read-through of stop codons on chromosomal genes (320 genes in *E. coli* terminate in UAG, including 44 essential genes); this strategy will therefore interfere with cellular protein synthesis and potentially disturb cellular physiology.

Despite these disadvantages, we have successfully developed an orthogonal ribosome which reads orthogonal mRNA codons with enhanced efficiency compared to natural ribosomes.

**SUMMARY OF THE INVENTION**

Unlike the progenitor ribosome in natural cells, orthogonal ribosomes are not responsible for synthesizing the proteome, and it is therefore possible to further diverge their function. However, this possibility had not been realised in the prior art. We have now demonstrated the first example of synthetic evolution of ribosome function in living cells. We have shown that orthogonal ribosomes can be evolved to decode more efficiently a range of extended codons using tRNAs with extended anticodon loops. The evolved orthogonal ribosome, ribo-X, preferentially reads quadruplet codons with extended anticodon tRNAs and can show specificity for Watson-Crick base pairs at the fourth position of the codon-anticodon interaction. Ribo-X also improves amber suppression by amber suppressor tRNAs. Finally, we have provided experimental support for a model which explains the mode of action of ribo-X, and implicates the 530 loop, in the ribosome decoding centre, in functional interactions with RF1.

In a first aspect of the present invention, therefore, there is provided an evolved orthogonal ribosomal RNA which possesses an enhanced efficiency of tRNA-dependent reading of orthogonal mRNA codons.

The rRNA of the invention differs from orthogonal rRNA (O-rRNA) molecules of the prior art, in that it not only shows specificity for orthogonal mRNA (O-mRNA), it shows an improved efficiency of translation of orthogonal mRNA codons compared to known orthogonal or natural ribosomes.

As noted above, although the prior art does document the reading of quadruplet codons by natural ribosomes, the efficiency of such reading is at most 20% of the efficiency with which triplet codons are read. In contrast, evolved O-ribosomes according to the invention are able to decode O-codons, such as quadruplet codons, approximately 10 times more efficiently than the same O-ribosomes can decode natural triplet codons. Moreover, they are more efficient at decoding quadruplet codons than non-evolved natural or O-ribosomes.

An orthogonal RNA codon, as used herein, is a codon which does not encode one of the 20 natural amino acids in the natural genetic code. Unnatural amino acids have been incorporated into proteins using modified tRNA which is charged with an unnatural amino acid, in place of the natural tRNA; however, this has previously been achieved using natural codons, both changing their specificity though modification of tRNA. By evolving a ribosome to decode orthogonal codons, such as extended codons, more efficiently, we have taken a different approach and developed an artificial alternative to the natural genetic code. Moreover, we have improved the efficiency of incorporation of amino acids into polypeptides using orthogonal tRNA, improving the efficiency of production of proteins incorporating natural and/or non-natural amino acids using mRNA with an artificial genetic code.

Increased efficiency can be measured, for example, by comparing the relative concentrations of an antibiotic to which resistance is conferred by an O-mRNA encoding an antibiotic resistance gene. For example, an evolved O-ribosome according to the invention is able to confer resistance to chloramphenicol acetyltransferase at a concentration 10 times higher when translating a mRNA comprising an orthogonal codon than when translating a mRNA comprising only triplet codons.

Preferably, the orthogonal mRNA codons are extended codons or stop codons. Advantageously, the orthogonal mRNA codon is a quartet or a triplet codon.

Preferably the orthogonal mRNA comprises one or more amber stop codons, preferably two or more amber stop codons, preferably three or more amber stop codons, preferably four or more, amber stop codons, preferably five or more amber stop codons, preferably six or more amber stop codons, preferably seven or more amber stop codons, preferably ten or more amber stop codons, or even more. The advantage of these embodiment(s) is that in the prior art, multiple amber stop codons lead to a dramatic reduction in translation efficiency, whereas according to the present invention these mRNAs are translated at greatly enhanced efficiency. This advantage is correspondingly greater, the greater the number of amber stop codons present in the mRNA of interest.

The orthogonal rRNA of the present invention is preferably a 16S rRNA, 16S rRNA forms the A-site in the ribosome and is responsible for binding of the extended anticodon tRNA to the ribosome.

Preferably, the orthogonal rRNA of the invention is a mutated 16S rRNA. The 530 loop of 16S rRNA is proximal to the codon-anticodon helix, preferably, the mutated 16S rRNA is mutated in the 530 loop, between positions 529 and 535.

Preferably, the orthogonal 16S rRNA comprises A513G and U534A mutations. Advantageously this orthogonal 16SrRNA is incorporated into a mutant ribosome, which possesses A513G and U534A mutations, referred to herein as ribo-X.

According to a second aspect of the invention, there is provided a method for evolving an orthogonal rRNA molecule, comprising the steps of:

(a) providing one or more libraries of mutant orthogonal rRNA molecules and introducing the libraries into cells such that the orthogonal rRNA is incorporated into ribosomes to provide orthogonal ribosomes;

(b) providing one or more orthogonal mRNA molecules which (i) are not translated by natural ribosomes, and (ii) comprise one or more orthogonal mRNA codons;

(c) assaying the translation of the of the orthogonal mRNA and selecting the orthogonal rRNA molecules which translate the orthogonal mRNA,
wherein the assay in step (c) requires translation of one or more orthogonal mRNA codons in the orthogonal mRNA.

 Preferably, the libraries of orthogonal rRNA molecules are libraries of 16S rRNA molecules, advantageously mutated in the 530 loop, between positions 529 and 535. Preferably, the libraries of orthogonal rRNA molecules comprise A531G and U534A mutations.

 Preferably, the orthogonal mRNA encodes a selectable marker; this marker may, for example, promote cell survival. Examples of selectable markers include chloramphenicol acetyltransferase, which allows the cell to survive exposure to chloramphenicol; cells which express CAT are thus selectable over cells that do not or do so less efficiently.

 The orthogonal rRNA of the invention is useful in a variety of translation systems. For example, it can be used to improve systems which incorporate unnatural amino acids into cells. Accordingly, the invention provides a method for incorporating an unnatural amino acid into a polypeptide, comprising the steps of:

 (a) providing a mRNA molecule comprising a stop codon in a reading frame thereof, wherein read-through of the stop coding can result in the incorporation of an unnatural amino acid;
 (b) providing an orthogonal rRNA molecule according to any one of the claims, which reads the stop codon more efficiently than natural rRNA; and
 (c) using a suppressor tRNA to incorporate an unnatural amino acid into the polypeptide encoded by the mRNA molecule.

 Preferably, the stop codon is a UAG amber stop codon; advantageously, the orthogonal rRNA molecule is an orthogonal rRNA molecule according to the first aspect of the invention.

 In a further aspect, there is provided a cell comprising two or more protein translation mechanisms, wherein:

 (a) a first mechanism is the natural translation mechanism wherein mRNA is translated by a ribosome in accordance with the natural genetic code;
 (b) a second mechanism is an artificial mechanism, in which orthogonal mRNA comprising orthogonal codons is translated by an orthogonal ribosome; wherein the orthogonal codons in the orthogonal mRNA are

 (i) not translated by the natural ribosome, or
 (ii) translated less efficiently by the natural ribosome than by the orthogonal ribosome, or
 (iii) translated into different polypeptides by the orthogonal ribosome and the natural ribosome.

 The orthogonal codons are preferably extended codons, and advantageously quadruplet codons.

 Alternatively, the orthogonal codons are stop codons, such as amber stop codons.

 Preferably, the orthogonal ribosome in the cell incorporates an orthogonal rRNA according to the first aspect of the invention.

 BRIEF DESCRIPTION OF THE FIGURES

 FIG. 1. Design of ribosome decoding libraries. A. Structure of a tRNA anticodon stem loop (yellow) bound to mRNA (purple) in the A site of the ribosome (green). The 530 loop is shown in orange. B. Secondary structure of the 530 loop. The boxed sequences form a pseudo knot, Ψ is pseudouridine and m7G is 7-methyl guanosine. C. The sequence of ribosome decoding libraries. 3D structure figures were created using PyMol v0.99 and PDB ID 1IBM.

 FIG. 2. Selection of orthogonal ribosomes for improved decoding of quadruplet codons. A. Schematic of the selection. Quadruplet codons on an orthogonal chloramphenicol acetyl transferase mRNA (purple) are decoded by orthogonal ribosomes (green) using extended anticodon tRNAs (yellow). The fidelity of incorporation is ensured by using serine inserting tRNAs and quadruplet codons at sites in the protein that require serine. Cells containing ribosome library members with improved quadruplet decoding are selected on chloramphenicol.

 B. The anticodon stem loop sequences of the UAGA and UCCU decoding tRNAs used. C. The sequence surrounding the quadruplet codons in O-cat. The variable quadruplet codons “Quad” are denoted “mmn”. The O-frame UAGA sequence shows the mutations made to test the competition between quadruplet and triplet decoding.

 FIG. 3. Selection and characterization of ribosomes with enhanced tRNA dependent decoding of quadruplet codons A. The selection of ribosomes that decode UAGA and AGGA codons, using cognate tRNAs derived from tRNAser2. The top sequence trace shows the 16S rRNA before selection, while the lower traces show the convergence of the pool (sequencing from all colonies surviving a selection on chloramphenicol plates). B. The sequences of individual clones isolated from each selection and the enhancement in ribosome decoding of UAGA or AGGA codons with cognate tRNAs in O-cat (xxxx103,xxxx146)/tRNAser2(yyy). C. The enhancement in decoding UAGA codons in the O-cat (UAGA103, UAGA146) gene with ribo-X is dependent on tRNAser2(UCUA).

 FIG. 4. The effect of ribo-X on decoding quadruplet codons using several extended anticodon tRNAs derived from tRNAser2. For the progenitor O-ribosome and ribo-X the chloramphenicol resistance in mg/ml-1 with O-cat (XXXX103, XXXX146)/tRNAser2(YYY) is shown, along with the fold enhancement conferred by ribo-X. The data for UAGG, UAGC, UAGU and UAG codons are for a reporter with a single selector codon at position 103 in O-cat, because the activity was too low to measure accurately in the two codon construct.

 FIG. 5. The efficiency of ribo-X in decoding the UAGA quadruplet codon. Thin-layer chromatography (TLC) showing the acetylation of chloramphenicol (Cm) to acetylated chloramphenicol (Acm) by chloramphenicol acetyl transferase produced from either O-cat or O-cat (UAGA103, UAGA146).

 FIG. 6. The specificity of ribo-X. A. Chloramphenicol resistance of cells containing O-cat (UAGA103, UAGA146)/tRNAser2(UCUA) and ribo-X B. TLC labelled as in FIG. 5, using constructs as in FIG. 6 panel A.
FIG. 8. Design of ribosome decoding libraries. A. Structure of a tRNA anticodon stem loop (yellow) bound to mRNA (purple) in the A site of the ribosome (green). The 530 loop is shown in orange. B. Structural model of RF-1 (blue) bound in the A-site of the ribosome C. Secondary structure of the 530 loop. The boxed sequences form a pseudo knot; "G" is pseudouridine and a "G" is 7-methyl guanosine. D. The sequence of ribosome decoding libraries. 3D structure figures were created using Pymol v0.99 and PDB IDs 11BM and 2B64.

FIG. 9. Selection and phenotypic characterization of ribo-X. A. The selection of ribosomes that decode UAGA and UAG codons, using cognate tRNAs derived from tRNA\textsuperscript{\textasciitilde}. The top sequence trace shows the 16S rRNA before selection, while the lower traces show the emergence of the pool (sequencing from all colonies surviving a selection on chloramphenicol plates). B. The ribo-X, tRNA\textsuperscript{\textasciitilde} (UCUA) dependent enhancement in decoding UAGA codons in the O-cat (UAGA103, UAGA146) gene measured by survival on chloramphenicol. C. As in B, but measuring CAT activity directly. Thin-layer chromatography (TLC) showing the acetylation of chloramphenicol (Cm) to acetylated chloramphenicol (AcCm) by CAT produced from either O-cat or O-cat (UAGA103, UAGA146).

FIG. 10. The translational fidelity of ribo-X is comparable to that of the natural ribosome. A. Translation of O-gst-maLE is dependent on ribo-X or the O-ribosome. B. Ribo-X synthesizes proteins of identical composition to those synthesized by the wild-type ribosome, as judged by electrospray ionization mass spectrometry. The electrospray ionization spectra of MBP synthesized by ribo-X, the progenitor O-ribosome or the wild-type ribosome is shown. Each ribosome was used to synthesize the GST-MBP protein, which was purified on glutathione sepharose and subject to thrombin cleavage at a site in the linker (FIG. 16). The resulting pairs of fragments have identical electrospray ionization spectra (Found: O-ribosome 44984 Da, ribo-X 44984 Da, wt ribosome 44984 Da, expected 44981 Da). C. The translational error frequency measured by \textsuperscript{35}S-cysteine mis-incorporation is indistinguishable for ribo-X and the natural ribosome. GST-MBP was synthesized by each ribosome in the presence of \textsuperscript{35}S-cysteine, purified on glutathione sepharose and digested with thrombin. The left panel shows a coomassie stain of the thrombin digest. The un-annotated bands result primarily from the thrombin preparation. The right panel shows \textsuperscript{35}S labelling of proteins in a similar gel, imaged using a Storm Phosphoimager, a coomassie stain of the \textsuperscript{35}S gel is shown in FIG. 19. Lanes 1-3 show thrombin cleavage reactions of purified protein derived from cells containing pSC101-\textsuperscript{\textasciitilde}-ribo-X & pGST-maLE, pSC101-\textsuperscript{\textasciitilde}-O-ribosome and pGST-maLE, and pSC101-\textsuperscript{\textasciitilde}-BD and pgst-maLE. Lane 4 is a negative control in which cells lacking a GST-maLE gene fusion were treated identically to the other samples. The size markers are pre-stained standards (Bio-Rad 161-0305) D. The translational fidelity of ribo-X is comparable to that of the natural ribosome as measured by a dual luciferase assay. In this system a C-terminal firefly luciferase is mutated at codon K529(AAA), which codes for an essential lysine residue. The extent to which the mutant codon is misread by tRNA\textsuperscript{\textasciitilde} (UUU) is determined by comparing the firefly luciferase activity resulting from the expression of the mutant gene to the wild-type firefly luciferase, and normalizing any variability in expression using the activity of the co-translated N-terminal Renilla luciferase. Previous work has demonstrated that measured firefly luciferase activities in this system result primarily from the synthesis of a small amount of protein that mis-incorporates lysine in response to the mutant codon, rather than a low activity resulting from the more abundant protein containing encoded mutations. In experiments examining the fidelity of ribo-X, lysate from cells containing pSC101-\textsuperscript{\textasciitilde}-ribo-X and pO-DLR and its codon 529 variants were assayed. Control experiments used lysates from cells containing pSC101-\textsuperscript{\textasciitilde}-O-ribosome and pO-DLR and its codon 529 variants or pwt-DLR and its variants. Assays on pO-DLR in the presence and absence of the orthogonal ribosome or ribo-X indicate that greater than 98% of translation on pO-DLR is derived from ribo-X or the orthogonal ribosome (FIG. 17), confirming that the fidelity measurements on pO-DLR reflect the activity of ribo-X.

FIG. 11. A. Ribo-X enhances the efficiency of BpaRS/ttRNA\textsubscript{AcCm} dependent unnatural amino acid incorporation in response to single and double UAG codons. In each lane an equal volume of protein purified from g-histidine sepharose under identical conditions is loaded. Ribo-X is produced from pSC101-\textsuperscript{\textasciitilde}-ribo-X derived tRNA, Bpa is p-benzoyl-L-phenylalanine. BpaRS is p-benzoyl-L-phenylalanyl-tRNA synthetase. BpaRS/ttRNA\textsubscript{AcCm} are produced from pSUPBpa\textsuperscript{23} which contains six copies of MtJrRNA\textsubscript{AcCm} and is the most efficient unnatural amino acid incorporation vector reported to date. (UAG)\textsubscript{n} describes the number of stop codons (n) between gst and maLE in O-gst(UAG)\textsubscript{n}maLE or gst(UAG)\textsubscript{n}maLE. Lane 10 is from a different gel. The markers are as described in FIG. 9. B. The mass of protein expressed from O-gst(UAG)\textsubscript{n}maLE by ribo-X is as expected for the incorporation of 2 Bpas. Purified full-length protein was cleaved with thrombin to produce an Mbp fragment amenable to accurate mass determination. The found mass (45191) is identical to the expected mass for incorporation of two Bpas into Mbp (45191.6). The small peak at 45216 Da is the Na\textsuperscript{+} adduct. C & D. MS/MS fragmentation of chymotryptic peptides derived from GST-MBP synthesized by ribo-X and incorporating 2 Bpas. The spectra confirm Bpa incorporation at both the expected sites. The fragmentation sites for each fragment ion are illustrated above the spectra. B denotes Bpa.

FIG. 12 shows supplementary table 1.

FIG. 13 shows supplementary table 2.

FIG. 14 shows the anticodon stem loops of the tRNAs used.

FIG. 15 shows the context of UAGA and UAG selector codons in codon reporter genes.

FIG. 16 shows the linker region of the g-st-maLE expression construct. The codons mutated in gst(UAG)\textsubscript{n}maLE constructs are indicated. The thrombin cleavage site in GST-MBP is indicated.

FIG. 17 shows the ribosome dependence of O-DLR derived renilla luciferase (O-R-luc) activity. O-ribosomes or ribo-X lead to a 40-45 fold activation, indicating that in the presence of O-ribosomes greater than 97% of the luciferase fusion is produced by O-ribosomes. The error bars indicate the standard error.

FIG. 18 shows the Ribo-X mediated enhanced unnatural amino acid incorporation efficiency is robust in minimal medium. Experiments were performed as described for FIG. 11A, except that minimal medium was used for expression. Similar results were observed when the efficiency of the progenitor ribosome was compared to Ribo-X. Molecular weight markers are as described in FIG. 10.

FIG. 19 shows 35S misincorporation in GST-MBP. The coomassie gel from which the 35S data in FIG. 10 was acquired and the corresponding 35S image are shown side-by-side. The alignment of the bands is indicated by the bounding boxes. The lanes are arranged identically to those in FIG. 10c.
DETAILED DESCRIPTION OF THE INVENTION

Definitions

As the term “orthogonal” is used herein, it refers to a nucleic acid, for example rRNA or mRNA, which differs from natural, endogenous nucleic acid in its ability to cooperate with other nucleic acids. Orthogonal mRNA, rRNA and tRNA are provided in matched groups (cognate groups) which cooperate efficiently. For example, orthogonal rRNA, when part of a ribosome, will efficiently translate matched cognate orthogonal mRNA, but not natural, endogenous mRNA. For simplicity, a ribosome comprising an orthogonal rRNA is referred to herein as an “orthogonal ribosome,” and an orthogonal ribosome will efficiently translate a cognate orthogonal mRNA.

An orthogonal codon or orthogonal mRNA codon is a codon in orthogonal mRNA which is only translated by a cognate orthogonal ribosome, or translated more efficiently, or differently, by a cognate orthogonal ribosome than by a natural, endogenous ribosome. Orthogonal is abbreviated to O (as in O-mRNA).

Thus, by way of example, orthogonal ribosome (O-ribosome) or orthogonal mRNA (O-mRNA) pairs are composed of: an mRNA containing a ribosome binding site that does not direct translation by the endogenous ribosome, and an orthogonal ribosome that efficiently and specifically translates the orthogonal mRNA, but does not appreciably translate cellular mRNAs.

“Evolved”, as applied herein for example in the expression “evolved orthogonal ribosome”, refers to the development of a function of a molecule through diversification and selection. For example, a library of rRNA molecules diversified at desired positions can be subjected to selection according to the procedures described herein. An evolved rRNA is obtained by the selection process.

As used herein, the term “mRNA” when used in the context of an O-mRNA O-ribosome pair refers to an mRNA that comprises an orthogonal codon which is efficiently translated by a cognate O-ribosome, but not by a natural, wild-type ribosome. In addition, it may comprise a mutant ribosome binding site (particularly the sequence from the AUG initiation codon upstream to −13 relative to the AUG) that efficiently mediates the initiation of translation by the O-ribosome, but not by a wild-type ribosome. The remainder of the mRNA can vary, such that placing the coding sequence for any protein downstream of that ribosome binding site will result in an mRNA that is translated efficiently by the orthogonal ribosome, but not by an endogenous ribosome.

As used herein, the term “rRNA” when used in the context of an O-mRNA O-ribosome pair refers to a rRNA mutated such that the rRNA is an orthogonal rRNA, and a ribosome containing it is an orthogonal ribosome, i.e., it efficiently translates only a cognate orthogonal mRNA. The primary, secondary and tertiary structures of wild-type ribosomal rRNAs are very well known, as are the functions of the various conserved structures (stems-loops, hairpins, hinges, etc.). O-rRNA typically comprises a mutation in 16S rRNA which is responsible for binding of tRNA during the translation process. It may also comprise mutations in the 3′ regions of the small rRNA subunit which are responsible for the initiation of translation and interaction with the ribosome binding site of mRNA.

The expression of an “O-rRNA” in a cell, as the term is used herein, is not toxic to the cell. Toxicity is measured by cell death, or alternatively, by a slowing in the growth rate by 80% or more relative to a cell that does not express the “O-mRNA.” Expression of an O-rRNA will preferably slow growth by less than 50%, preferably less than 25%, more preferably less than 10%, and more preferably still, not at all, relative to the growth of similar cells lacking the O-rRNA.

As used herein, the terms “more efficiently translates” and “more efficiently mediates translation” mean that a given O-mRNA is translated by a cognate O-ribosome at least 25% more efficiently, and preferably at least 2, 3, 4 or 8 or more times as efficiently as an O-mRNA is translated by a wild-type ribosome or a non-cognate O-ribosome in the same cell or cell type. As a gauge, for example, one may evaluate translation efficiency relative to the translation of an O-mRNA encoding chloramphenicol acetyl transferase using at least one orthogonal codon by a natural or non-cognate orthogonal ribosome.

As used herein, the term “corresponding to” when used in reference to nucleotide sequence means that a given sequence in one molecule, e.g., a 16S rRNA, is in the same position in another molecule, e.g., a 16S rRNA from another species. By “in the same position” is meant that the “corresponding” sequences are aligned with each other when aligned using the BLAST sequence alignment algorithm “BLAST 2 Sequences” described by Tatusova and Madden (1999, “Blast 2 sequences—a new tool for comparing protein and nucleotide sequences”, FEMS Microbiol. Lett. 174:247-250) and available from the U.S. National Center for Biotechnology Information (NCBI). To avoid any doubt, the BLAST version 2.2.11 (available for use on the NCBI website or, alternatively, available for download from that site) is used, with default parameters as follows: program, blastn; reward for a match, 1; penalty for a mismatch, −2; open gap and extend gap penalties 5 and 2, respectively; gap x dropoff, 50; expect 10.0; word size 11; and filter on.

As used herein, the term “selectable marker” refers to a gene sequence that permits selection for cells in a population that encode and express that gene sequence by the addition of a corresponding selection agent.

As used herein, the term “region comprising sequence” that interacts with mRNA at the ribosome binding site refers to a region of sequence comprising the nucleotides near the 3′ terminus of 16S rRNA that physically interact, e.g., by base pairing or other interaction, with mRNA during the initiation of translation. The “region” includes nucleotides that base pair or otherwise physically interact with nucleotides in mRNA at the ribosome binding site, and nucleotides within five nucleotides 5′ or 3′ of such nucleotides. Also included in this “region” are bases corresponding to nucleotides 722 and 723 of the E. coli 16S rRNA, which form a bulge proximal to the minor groove of the Shine-Delgarno helix formed between the ribosome and mRNA.

As used herein, the term “diversified” means that individual members of a library will vary in sequence at a given site. Methods of introducing diversity are well known to those skilled in the art, and can introduce random or less than fully random diversity at a given site. By “fully random” is meant that a given nucleotide can be any of G, A, T, or C (or in RNA, any of G, A, U and C). By “less than fully random” is meant that a given site can be occupied by more than one different nucleotide, but not all of G, A, T (U in RNA) or C, for example where diversity permits either G or A, but not U or C, or permits G, A, or U but not C at a given site.

As used herein, the term “ribosome binding site” refers to the region of an mRNA that is bound by the ribosome at the initiation of translation. As defined herein, the “ribosome binding site” of prokaryotic mRNAs includes the Shine-Delgarno consensus sequence and nucleotides −13 to +1 relative to the AUG initiation codon.
As used herein, the term "unnatural amino acid" refers to an amino acid other than the amino acids that occur naturally in protein. Non-limiting examples include: a p-acetyl-L-phenylalanine, a 3,4-octanediol-phenylalanine, an O-methyl-L-tyrosine, a p-propargyloxy phenylalanine, a p-propargyl-phenylalanine, an L-3-(2-naphthyl)alanine, a 3-methyl-phenylalanine, an O-4-allyl-L-tyrosine, a 4-propyl-L-tyrosine, a tri-o-acetyl-GlcNAcPe-serine, an L-Dopa, a fluorinated phenylalanine, an isopropyl-L-phenylalanine, a p-azido-L-phenylalanine, a p-acetyl-L-phenylalanine, a p-benzoyl-L-phenylalanine, an L-phosphoserine, a phosphothreonine, a phosphotyrosine, a p-bromophenylalanine, a p-aminophenylalanine, a 3-aminophenylalanine, an unnatural analogue of a tyrosine amino acid; an unnatural analogue of a glutamine amino acid; an unnatural analogue of a phenylalanine amino acid; an unnatural analogue of a serine amino acid; an unnatural analogue of a threonine amino acid; an alkyl, aryl, acyl, azido, cyano, halo, hydrazine, hydrazide, hydroxy, alkene, alkyl, ether, thiol, seleno, ester, thioacid, borate, boronate, phospho, phospho, phosphine, heterocyclic, enone, imine, aldhyde, hydrosulfonyl, keto, or amino substituted amino acid, or a combination thereof; an amino acid with a photoactivatable cross-linker; a spin-labeled amino acid; a fluorescent amino acid; a metal binding amino acid; a metal-containing amino acid; a radioactive amino acid; a photocaged and/or photoisomerizable amino acid; a biotin or biotin-analogue containing amino acid; a keto containing amino acid; an amino acid comprising polyethylene glycol or polyether; a heavy atom substituted amino acid; a chemically cleavable or photo cleavable amino acid; an amino acid with an elongated side chain; an amino acid containing a toxic group; a sugar substituted amino acid; a carbon-linked sugar-containing amino acid; a redox-active amino acid; an α-hydroxy containing amino acid; an amino thio acid; an α,α disubstituted amino acid; a β-amino acid, a cyclic amino acid other than proline or histidine, and an aromatic amino acid other than phenylalanine, tyrosine or tryptophan.

In our copending international patent application PCT/GB2006/002637 we describe the generation of orthogonal ribosome/mRNA pairs in which the ribosome binding site in the O-mRNA binds specifically to the O-ribosome.


Mutations in the SD sequence often lead to rapid cell lysis and death (Lee, K., Holland-Staley, C. A. & Cunningham, P. R., RNA 2, 1270-1285 (1996), Wood, T. K. & Peretti, S. W., Biotechnol. Bioeng 38, 891-906 (1991)). Such mutant ribosomes mis-regulate cellular translation and are not orthogonal. The sensitivity of cell survival to mutations in the ASD region is underscored by the observation that even a single change in the ASD can lead to cell death through catastrophic and global mis-regulation of proteome synthesis (Jacob, W. F., Sauter, M. & Dahlberg, A. E., Proc Natl Acad Sci USA 84, 4757-4761 (1987). Other mutations in the rRNA can lead to inadequacies in processing or assembly of functional ribosomes.

PCT/GB2006/002637 describes methods for tailoring the molecular specificity of duplicated E. coli ribosome mRNA pairs with respect to the wild-type ribosome and mRNAs to produce multiple orthogonal ribosome orthogonal mRNA pairs. In these pairs the ribosome efficiently translates only the orthogonal mRNA and the orthogonal mRNA is not an efficient substrate for cellular ribosomes. Orthogonal ribosomes as described therein that do not translate endogenous mRNAs permit specific translation of desired cognate mRNAs without interfering with cellular gene expression. The network of interactions between these orthogonal pairs is predicted and measured, and it is shown that orthogonal ribosome mRNA pairs can be used to post-transcriptionally program the cell with Boolean logic.

PCT/GB2006/002637 describes a mechanism for positive and negative selection for evolution of orthogonal translational machinery. The selection methods are applied to evolving multiple orthogonal ribosome mRNA pairs (O-ribosome O-mRNA). Also described is the successful prediction of the network of interactions between cognate and non-cognate O-ribosomes and O-mRNAs.

Here we provide new, further modified orthogonal ribosomes and methods for producing such O-ribosomes which expand the molecular decoding properties of the ribosome. Specifically, we evolve orthogonal ribosomes that more efficiently decode a set of quadruplet codons using tRNAs with extended antisense loops. Moreover, we provide a much-
nistic explanation of the enhancements we observe, and demonstrate that the evolved orthogonal ribosome is also substantially more efficient at decoding amber codons with amber suppressor tRNAs. We disclose evolved orthogonal ribosomes which enhance the efficiency of synthetic genetic code expansion. We provide cellular modules composed of an orthogonal ribosome and an orthogonal mRNA. These pairs function in parallel with, but independent of, the natural ribosome-mRNA pair in *Escherichia coli*. Orthogonal ribosomes do not synthesize the proteome and may be diverged to operate using different tRNA decoding rules from natural ribosomes. Here we demonstrate the evolution of an orthogonal ribosome (ribo-X) for the efficient, high fidelity decoding of codons such as amber codons placed within the context of an orthogonal mRNA in living cells. We combine ribo-X, orthogonal mRNAs and orthogonal aminoacyl-tRNA synthetase/tRNA pairs to substantially increase the efficiency of site-specific unnatural amino acid incorporation in *E. coli*. This advantageously allows the efficient synthesis of proteins incorporating unnatural amino acids at multiple sites, and/or minimizes the functional and/or phenotypic effects of truncated proteins for example in experiments that use unnatural amino acid incorporation to probe protein function in vivo. Orthogonal Codons

For the first time, we describe an evolved ribosome which is capable of translating an orthogonal mRNA codon, which means that the ribosome interprets mRNA information according to a code which is not the universal genetic code, but an orthogonal genetic code. This introduces a number of possibilities, including the possibility of having two separate genetic systems present in the cell, wherein cross-talk is eliminated by virtue of the difference in code, or of a mRNA molecule encoding different polypeptides according to which code is used to translate it.

An orthogonal codon, from which orthogonal genetic codes can be assembled, is a code which is other than the universal triplet code. Table 1 below represents the universal genetic code:

<table>
<thead>
<tr>
<th>SECOND NUCLEOTIDE</th>
<th>U</th>
<th>C</th>
<th>A</th>
<th>G</th>
</tr>
</thead>
<tbody>
<tr>
<td>UUU</td>
<td>ECU</td>
<td>UAU</td>
<td>UGU</td>
<td>U</td>
</tr>
<tr>
<td>Phenylalnine (Phe)</td>
<td>Serine</td>
<td>Tyrosine</td>
<td>Cysteine</td>
<td>U</td>
</tr>
<tr>
<td>UUC</td>
<td>ACA</td>
<td>AUA</td>
<td>AAC</td>
<td>G</td>
</tr>
<tr>
<td>Leucine (Leu)</td>
<td>Serine</td>
<td>Tyrone</td>
<td>Stop</td>
<td>A</td>
</tr>
<tr>
<td>GCC</td>
<td>GCA</td>
<td>CCA</td>
<td>CGG</td>
<td>G</td>
</tr>
<tr>
<td>Valine (Val)</td>
<td>Alanine</td>
<td>Aspartic</td>
<td>Asparagine</td>
<td>A</td>
</tr>
<tr>
<td>AUG</td>
<td>ACC</td>
<td>AAA</td>
<td>AGG</td>
<td>G</td>
</tr>
<tr>
<td>Methionine (Met)</td>
<td>Thr</td>
<td>Lysine</td>
<td>Arginine</td>
<td>A</td>
</tr>
</tbody>
</table>

Certain variations in this code occur naturally; for example, most animal mitochondria use AUA for methionine not isoleucine and all vertebrate mitochondria use AGA and AGG as chain terminators. Yeast mitochondria assign all codons beginning with CU to threonine instead of leucine (which is still encoded by UUA and UUG as it is in cytosolic mRNA). Plant mitochondria use the universal code, and this has permitted angiosperms to transfer mitochondrial genes to their nucleus with great ease. Violations of the universal code are far rarer for nuclear genes. A few unicellular eukaryotes have been found that use one or two (of their three) STOP codons for amino acids instead.

The vast majority of proteins are assembled from the 20 amino acids listed above even though some of these may be chemically altered, e.g., by phosphorylation, at a later time. However, two cases have been found in nature where an amino acid that is not one of the standard 20 is inserted by a tRNA into the growing polypeptide.

Selenocysteine. This amino acid is encoded by UGA. UGA is still used as a chain terminator, but the translation machinery is able to discriminate when a UGA codon should be used for selenocysteine rather than STOP. This codon usage has been found in certain Archaea, eubacteria, and animals (humans synthesize 25 different proteins containing selenium).

Pyrolysine. In one gene found in a member of the Archaea, this amino acid is encoded by UAG. How the translation machinery knows when it encounters UAG whether to insert a tRNA with pyrolysine or to stop translation is not yet known.

All of the above are, for the purposes of the present invention, considered to be part of the universal genetic code. The present invention enables novel codes, not previously known in nature, to be developed and used in the context of orthogonal mRNA/tRNA pairs.

Selection for Orthogonal Ribosomes

A selection approach for the identification of orthogonal ribosome orthogonal mRNA pairs, or other pairs of orthogonal molecules, requires selection for translation of orthogonal codons in O-mRNA. The selection is advantageously positive...
selection, such that cells which express O-mRNA are selected over those that do not, or do so less efficiently.

A number of different positive selection agents can be used. The most common selection strategies involve conditional survival on antibiotics. Of these positive selections, the chloramphenicol acetyl-transferase gene in combination with the antibiotic chloramphenicol has proved one of the most useful. Others as known in the art, such as ampicillin, kanamycin, tetracycline or streptomycin resistance, among others, can also be used.

O-mRNA/O-rRNA pairs can be used to produce an orthogonal transcript in a host cell, for example CAT, that can only be translated by the cognate orthogonal ribosome, thereby permitting extremely sensitive control of the expression of a polypeptide encoded by the transcript. The pairs can thus be used to produce a polypeptide of interest by, for example, introducing mutations to encode such a pair in the cell, where the orthogonal mRNA encodes the polypeptide of interest. The translation of the orthogonal mRNAs by the orthogonal ribosome results in production of the polypeptide of interest. It is contemplated that polypeptides produced in cells encoding orthogonal mRNA orthogonal ribosome pairs can include unnatural amino acids.

The methods described herein are applicable to the selection of orthogonal mRNA orthogonal rRNA pairs in species in which the O-mRNA comprises orthogonal codons which are translated by the O-rRNA. Thus, the methods are broadly applicable across prokaryotic and eukaryotic species, in which this mechanism is conserved. The sequence of 16S rRNA is known for a large number of bacterial species and has itself been used to generate phylogenetic trees defining the evolutionary relationships between the bacterial species (reviewed, for example, by Ludwig & Schleifer, 1994, FEMS Microbiol. Rev. 15: 155-73; see also Bergey’s Manual of Systematic Bacteriology Volumes 1 and 2, Springer, George M. Garrity, ed.). The Ribosomal Database Project II (Cole J R, Chai B, Farris R J, Wang Q, Kulam S A, McGarrell D M, Garrity G M, Tiedje J M, Nucleic Acids Res. (2005) 33(Database issue):D294-D296, doi: 10.1093/nar/gki038) provides, in release 9.28 (Jun. 17, 2005), 155,708 aligned and annotated 16S rRNA sequences, along with online analysis tools.

Phylogenetic trees are constructed using, for example, 16S rRNA sequences and the neighbour joining method in the ClustalW sequence alignment algorithm. Using a phylogenetic tree, one can approximate the likelihood that a given set of mutations (on 16S rRNA and a codon in mRNA) that render the set orthogonal with respect to each other in one species will have a similar effect in another species. Thus, the mutations rendering mRNA/16S rRNA pairs orthogonal with respect to each other in one species would be more likely to result in orthogonal mRNA/orthogonal ribosome pairs in another member of the same family (e.g., Salmonella) than in a member of a different family on the phylogenetic tree.

In some instances, where bacterial species are very closely related, it may be possible to introduce corresponding 16S rRNA and mRNA mutations that result in orthogonal molecules in one species into the closely related species to generate an orthogonal mRNA orthogonal rRNA pair in the related species. Also where bacterial species are closely related (e.g., for E. coli and Salmonella species), it may be possible to introduce orthogonal 16S rRNA and orthogonal mRNA from one species directly to the closely related species to obtain a functional orthogonal mRNA orthogonal ribosome pair in the related species.

Alternatively, where the species in which one wishes to identify orthogonal mRNA orthogonal ribosome pairs is not closely related (e.g., where they are not in the same phylogenetic Family) to a species in which a set of pairs has already been selected, one can use selection methods as described herein to generate orthogonal mRNA orthogonal ribosome pairs in the desired species. Briefly, one can prepare a library of mutated orthogonal 16S rRNA molecules. The library can then be introduced to the chosen species. One or more O-mRNA sequences can be generated which comprise a sequence encoding a selection polypeptide as described herein using one or more orthogonal codons (the bacterial species must be sensitive to the activity of the selection agents, a matter easily determined by one of skill in the art). The O-mRNA library can then be introduced to cells comprising the O-rRNA library, followed by positive selection for those cells expressing the positive selectable marker in order to identify orthogonal ribosomes that pair with the O-mRNA.

The methods described herein are applicable to the identification of molecules useful to direct translation or other processes in a wide range of bacteria, including bacteria of industrial and agricultural importance as well as pathogenic bacteria. Pathogenic bacteria are well known to those of skill in the art, and sequence information, including not only 16S rRNA sequence, but also numerous mRNA coding sequences, are available in public databases, such as GenBank. Common, but non-limiting examples include, e.g., Salmonella species, Clostridium species, e.g., Clostridium botulinum and Clostridium perfringens, Staphylococcus sp., e.g., Staphylococcus aureus; Campylobacter species, e.g., Campylobacter jejuni, Yersinia species, e.g., Yersinia pestis, Yersinia enterocolitica and Yersinia pseudotuberculosis; Listeria species, e.g., Listeria monocytogenes, Vibrio species, e.g., Vibrio cholerae, Vibrio parahaemolyticus and Vibrio vulnificus; Bacillus cereus, Aeromonas species, e.g., Aeromonas hydrophila, Shigella species, Streptococcus species, e.g., Streptococcus pyogenes, Streptococcus faecalis, Streptococcus faecium, Streptococcus pneumoniae, Streptococcus durans, and Streptococcus avium, Mycobacterium tuberculosis, Klebsiella species, Enterobacter species, Proteus species, Citrobacter species, Aerobacter species, Providencia species, Neisseria species, e.g., Neisseria gonorrhoea and Neisseria meningitidis, Haemophilus species, e.g., Haemophilus influenzae, Helicobacter species, e.g., Helicobacter pylori, Bordetella species, e.g., Bordetella pertussis, Serratia species, and pathogenic species of E. coli, e.g., Enterotoxigenic E. coli (ETEC), enteropathogenic E. coli (EPEC) and enterohemorrhagic E. coli O157:H7 (EHEC).

Release Factor 1/Amber Codons

Advantageously, to maximize the efficiency of full-length protein synthesis with respect to truncated protein, the effects of release factor 1 (RF-1)-mediated chain termination would be minimized for the expression of a gene of interest, while the decoding of chromosomal amber stop codons would remain unaltered. We conceived to use recently described orthogonal ribosome-mRNA pairs to address this challenge (see examples and FIG. 7).

Unlike the natural ribosome the orthogonal ribosome is not responsible for synthesizing the proteome, and is therefore tolerant to mutations in the highly conserved rRNA that cause lethal or dominant negative effects in the natural ribosome. Orthogonal ribosomes may therefore be advantageously evolved towards decreased RF-1 binding and increased rRNA dependent amber suppression according to the present invention. Moreover, increased amber suppression within the context of an orthogonal ribosome has the advantage of operating
on amber codons within orthogonal mRNAs whilst advantageously also not increasing suppression of chromosomal stop codons.

We disclose the synthetic evolution of an orthogonal ribosome (ribo-X) for the efficient, high fidelity, suppressor tRNA dependent decoding of amber stop codons placed within the context of an orthogonal mRNA in living cells. Ribozyme-X may preferably be combined with orthogonal mRNAs and orthogonal aminoacyl-tRNA synthetase/tRNA pairs to advantageously significantly increase the efficiency of site-specific unnatural amino acid incorporation in E. coli. This increase in efficiency makes it possible to synthesize proteins incorporating unnatural amino acids at multiple sites, and minimizes the functional and phenotypic effects of truncated proteins in vivo. This has clear industrial application and utility, for example in the manufacture of proteins incorporating unnatural amino acids.

Since ribo-X increases suppression of amber stop codons by suppressor tRNAs of distinct sequence and structure, we suggest that ribo-X operates by decreasing its functional interaction with RF-1, allowing the suppressor tRNAs to more efficiently compete for A-site binding in the presence of a UAG codon on the mRNA. Variations or optimisation of the strategy disclosed here may yield further increases in amber suppression while maintaining translational fidelity. In this regard it is encouraging that both biochemical evidence suggests distinct conformations of the decoding centre are recognized by tRNAs and RF-1 (Youngman et al Cold Spring Harb Symp Quant Biol 71, 545-549 (2006)) and that we have been able to select combinations of mutations for which RF-1 mediated termination is decreased without decreasing the fidelity of tRNA decoding. These observations surprisingly indicate that the molecular determinants for the fidelity of tRNA decoding and RF-1 binding need not be tightly coupled and thus further independent modulation within the orthogonal system is enabled by the present invention.

By improving amber suppression efficiency on the orthogonal ribosome it is now possible to diverge the decoding properties of the orthogonal ribosome from those of the cellular ribosome such that the same insertion signal is read with a different efficiency on cellular and orthogonal mRNAs within the same cell as demonstrated herein. A conceptually similar, but mechanistically distinct, strategy involving localization of specialized translational components is used by nature to direct the incorporation of selenocysteine in response to a subset of UGA codons. Thus the invention may find application in similar strategies to enhance the efficiency of synthetic eukaryotic genetic code expansion. Since the meaning of codons on any mRNA are set by the translational machinery that decodes that mRNA, it may be possible to use our approach to write entirely new genetic codes on orthogonal mRNAs and to undo the "frozen accident" of the existing genetic code. For example, it may be possible to use tRNAs that are poor substrates for the cellular ribosome but are efficiently decoded by evolved orthogonal ribosomes to write independent and parallel codes (orthogonal genetic codes). Orthogonal genetic codes may form a basis for a biological "virtual operating system" that further expands the information storage and genetic encoding capacity of the cell.

**Bacterial Transformation**

The methods described herein rely upon the introduction of foreign or exogenous nucleic acids into bacteria. Methods for bacterial transformation with exogenous nucleic acid, and particularly for rendering cells competent to take up exogenous nucleic acid, is well known in the art. For example, Gram negative bacteria such as E. coli are rendered transformation competent by treatment with multivalent cationic agents such as calcium chloride or rubidium chloride. Gram positive bacteria can be incubated with degradative enzymes to remove the peptidoglycan layer and thus form protoplasts. When the protoplasts are incubated with DNA and polyethylene glycol, one obtains cell fusion and concomitant DNA uptake. In both of these examples, if the DNA is linear, it tends to be sensitive to nucleases so that transformation is most efficient when it involves the use of covalently closed circular DNA. Alternatively, nuclease-deficient cells (RecBCD strains) can be used to improve transformation.

**Electroporation** is also well known for the introduction of nucleic acid to bacterial cells. Methods are well known, for example, for electroporation of Gram negative bacteria such as E. coli, but are also well known for the electroporation of Gram positive bacteria, such as Enterococcus faecalis, among others, as described, e.g., by Dunny et al., 1991, Appl. Environ. Microbiol. 57: 1194-1201.

**EXAMPLES**

**Example 1**

**Evolution of an Orthogonal Ribosome**

**Design of a Ribosome Decoding Centre Library for Enhanced Quadruplet Decoding**

While the detailed mechanism of quadruplet decoding is controversial and may differ for different tRNA/codon pairs, it is clear that an early and essential step in decoding is the binding of the extended anticodon tRNA to the A-site of the ribosome in response to the quadruplet codon. Since the A-site is the gateway to the tRNA translocation corridor composed of the A, P and E sites, and is the primary site of codon-anticodon proofreading for elongator tRNAs, we reasoned that combinations of mutations in 16S tRNA, which forms the A-site, might yield an variant A-site that functions more efficiently with an extended anticodon loop tRNA.

To design a library we examined the structures of normal tRNA anticodon stem loops bound to the ribosomal A site and may differ for different tRNA/codon pairs, it is clear that an early and essential step in decoding is the binding of the extended anticodon tRNA to the A-site of the ribosome in response to the quadruplet codon. Since the A-site is the gateway to the tRNA translocation corridor composed of the A, P and E sites, and is the primary site of codon-anticodon proofreading for elongator tRNAs, we reasoned that combinations of mutations in 16S tRNA, which forms the A-site, might yield an variant A-site that functions more efficiently with an extended anticodon loop tRNA.

To design an A-site library we examined the structures of normal tRNA anticodon stem loops bound to the ribosomal A site and may differ for different tRNA/codon pairs, it is clear that an early and essential step in decoding is the binding of the extended anticodon tRNA to the A-site of the ribosome in response to the quadruplet codon. Since the A-site is the gateway to the tRNA translocation corridor composed of the A, P and E sites, and is the primary site of codon-anticodon proofreading for elongator tRNAs, we reasoned that combinations of mutations in 16S tRNA, which forms the A-site, might yield an variant A-site that functions more efficiently with an extended anticodon loop tRNA.

To design an A-site library we examined the structures of normal tRNA anticodon stem loops bound to the ribosomal A site and may differ for different tRNA/codon pairs, it is clear that an early and essential step in decoding is the binding of the extended anticodon tRNA to the A-site of the ribosome in response to the quadruplet codon. Since the A-site is the gateway to the tRNA translocation corridor composed of the A, P and E sites, and is the primary site of codon-anticodon proofreading for elongator tRNAs, we reasoned that combinations of mutations in 16S tRNA, which forms the A-site, might yield an variant A-site that functions more efficiently with an extended anticodon loop tRNA.

To design an A-site library we examined the structures of normal tRNA anticodon stem loops bound to the ribosomal A site and may differ for different tRNA/codon pairs, it is clear that an early and essential step in decoding is the binding of the extended anticodon tRNA to the A-site of the ribosome in response to the quadruplet codon. Since the A-site is the gateway to the tRNA translocation corridor composed of the A, P and E sites, and is the primary site of codon-anticodon proofreading for elongator tRNAs, we reasoned that combinations of mutations in 16S tRNA, which forms the A-site, might yield an variant A-site that functions more efficiently with an extended anticodon loop tRNA.

To design an A-site library we examined the structures of normal tRNA anticodon stem loops bound to the ribosomal A site and may differ for different tRNA/codon pairs, it is clear that an early and essential step in decoding is the binding of the extended anticodon tRNA to the A-site of the ribosome in response to the quadruplet codon. Since the A-site is the gateway to the tRNA translocation corridor composed of the A, P and E sites, and is the primary site of codon-anticodon proofreading for elongator tRNAs, we reasoned that combinations of mutations in 16S tRNA, which forms the A-site, might yield an variant A-site that functions more efficiently with an extended anticodon loop tRNA.
UAGA146)/tRNA<sup>iso</sup> (UCUA) and the O-ribosome had an IC<sub>50</sub> on chloramphenicol of 25 mg ml<sup>-1</sup>, and cells containing O-cat (AGGA103, AGGA146)/tRNA<sup>iso</sup> (UCUA) had an IC<sub>50</sub> on chloramphenicol of 80 mg ml<sup>-1</sup>. For comparison the wild-type O-ribosome supports growth to 500 mg ml<sup>-1</sup> chloramphenicol in the presence of a cognate O-ribosome.

To select mutant ribosomes that more efficiently decode the UAGA codon we combined each orthogonal ribosome library (N5-N9) with O-cat (UAGA103, UAGA146)/tRNA<sup>iso</sup> (UCUA) and challenged the cells to grow on chloramphenicol concentrations at which the O-ribosome does not support growth (FIG. 2). While no clones containing insertions or deletions survived for libraries N5, N6, N8 and N9, suggesting that the 530 loop is intolerant to longer or shorter sequences of any composition, clones did survive from the N7 library on 50 mg ml<sup>-1</sup> chloramphenicol. We isolated and sequenced ten plasmids encoding surviving N7 library members. For the UAGA decoding selection, all clones sequenced were identical, and contained the mutations A531G and U534A. (FIG. 3). Next, we repeated the selection using the AGGA reporter and cognate tRNA. In this selection we found that the library also converges, to sequences similar to, and in some cases identical to, the sequence selected for decoding UAGA (FIG. 3). We combined the ribosomes from both selections with either the AGGA or UAGA reporters and found that, as expected, the UAGA selected ribosome decodes UAGA most efficiently. We also found that the UAGA selected ribosome is among the most efficient ribosomes for AGGA decoding. We therefore decided to characterize the A531G, U534A mutant ribosome, which we refer to as ribo-X, in more detail.

Example 2

Analysis of Ribo-X

Ribo-X Enhances tRNA Dependent Reading of UAGA Quadruplet Codons

To investigate whether ribo-X reads quadruplet codons in a tRNA dependent manner, we co-transformed ribo-X and O-cat (UAGA103, UAGA146) and measured chloramphenicol resistance. We find that ribo-X does not significantly contribute to +1 frame shifting in the absence of an extended anticodon tRNA (Cm resistance <1 mg ml<sup>-1</sup>) (FIG. 3).

To measure the extent to which ribo-X enhances tRNA<sup>iso</sup> (UCUA) dependent decoding of the UAGA codon we compared the chloramphenicol resistance of cells transformed with O-cat (UAGA103, UAGA146)/tRNA<sup>iso</sup> (UCUA) and either ribo-X or the progenitor O-ribosome. We find that the ribo-X containing cells survive on concentrations of chloramphenicol five times higher (125 mg ml<sup>-1</sup>) than cells containing the progenitor O-ribosome (25 mg ml<sup>-1</sup>) (FIG. 3). The enhanced quadruplet decoding was further confirmed by in vitro CAT assays (FIG. 5), which also confirm that resistance is linear with chloramphenicol acetyl transferase activity (not shown). To ascertain if the enhanced activity of ribo-X on quadruplet codons is at the expense of triplet decoding we compared the chloramphenicol resistance conferred by ribo-X to that conferred by the progenitor O-ribosome on cells containing O-cat. We find no difference in activity; both ribosomes support growth to 500 mg ml<sup>-1</sup>, indicating that ribo-X is efficient at decoding triplet codons.

Ribo-X Shows Specifity for Fourth Base Interaction & Preferentially Decodes Quadruplet Codons with Extended Anticodon tRNAs

We investigated the specificity of ribo-X for Watson-Crick base pairing in the fourth position of the codon-anticodon interaction by measuring the chloramphenicol acetyl transferase activity of ribo-X with O-cat (UAGN103, UAGN146)/tRNA<sup>iso</sup> (UCUA). We find that ribo-X shows a selectivity of more than ten-fold for the cognate A-U pair, over any other base-pair at the fourth position. (FIG. 6) consistent with previous reports for the natural ribosome<sup>35</sup>.

To investigate whether ribo-X preferentially decodes a quadruplet codon over a triplet codon, when supplied with an extended anticodon tRNA, we compared the chloramphenicol resistance conferred by an O-cat gene in which codon 103 is UAG and codon 104 begins with an A (O-frame UAGA, FIG. 2) with that conferred by an O-cat gene containing an in-frame UAGA quadruplet codon at position 103. We find that ribo-X and tRNA<sup>iso</sup> (UCUA) confer resistance to chloramphenicol up to 20 mg ml<sup>-1</sup> on the triplet codon reporter and up to 400 mg ml<sup>-1</sup> on the quadruplet codon reporter. These data suggest that less than 5% of the termination on quadruplet codons with ribo-X results from triplet decoding, and that with the extended anticodon tRNA, ribo-X prefers quadruplet over triplet decoding by approximately 10-fold.

Ribo-X Shows Increased Efficiency in Decoding Quadruplet Codons

To begin to explore the extent to which enhanced quadruplet decoding of UAGA and AGGA with ribo-X is portable to other extended anticodons, we first altered the anticodon of the tRNA to GCCU, CCUA, or ACUA and altered the codons at position 103 in the O-cat gene to their Watson-Crick complement (UAGC, UAGG, UAGU). Ribo-X shows an up to 8-fold increase in efficiency at decoding quadruplet codons with respect to the progenitor O-ribosome (FIG. 4). In addition we find that ribo-X enhances translational efficiency 2.5-fold with a CCCU reporter in the presence of a cognate extended anticodon tRNA.

Ribo-X Increases Amber Decoding and UAGN decoding by Decreasing Functional Interactions with Release Factor.

The decoding enhancement with UAGN codons is generally larger than that observed with AGGA and CCCU codons, and this prompted us to ask whether ribo-X enhances decoding of UAGN codons in part by decreasing its functional interaction with release factor 1 (RF1). The ribosome binds RF1 in response to amber codons in the ribosomal A site, and causes peptide chain termination<sup>34</sup>. RF1-mediated termination is therefore believed to compete with amber suppressor tRNA mediated peptide chain elongation in response to an amber codon in the ribosomal A-site. Ribosomes that do not functionally interact with RF1 but are still able to perform protein synthesis and function with NCUA tRNAs would be more efficient than un-evolved ribosomes at decoding UAGN codons. If the enhanced activity of ribo-X on UAGN codons were due in part to a decreased functional interaction with RF1 then ribo-X should be more efficient at decoding the amber stop codon (UAG) with an amber suppressor tRNA. Indeed we find that when we contract the anticodon from UCUA to CUA, the resulting suppressor tRNA is 8 times more efficient at decoding an amber codon at position 103 in O-cat with ribo-X than with the progenitor O-ribosome (FIG. 4). This suggests that a major mechanism by which ribo-X increases its efficiency on UAGN codons is by decreasing its functional interaction with release factor, and provides evidence for a functional interaction between the 530 loop of the ribosome and RF1 that is consistent with, but not predicted by, the 5.9 Å X-ray structure of RF1 bound to the ribosome<sup>35</sup>. In contrast to temperature sensitive mutants in the essential RF1 protein, mutants in the cellular ribosome that allow transient increases in suppression across all mRNAs at the expense of cellular viability<sup>33, 36, 37</sup>, or mutants in tRNA that
cause misreading of amber codons in the absence of a cognate tRNA, the effect of ribo-X is localized to the population of orthogonal mRNAs that it decodes. Ribo-X increases tRNA dependent amber suppression in a target gene without increasing read through of amber codons in natural cellular mRNAs and therefore does not perturb decoding of the natural transcriptome.

Ribo-X is Optimized for the 32-38 Pair in Extended Anticodon tRNAs

While we observe a strong effect on UAGN and UAG decoding we also see improvements, albeit more modest, in the efficiency of decoding the quadruplet codons AGGA and CCCU codons by cognate extended anticodon tRNAs (Fig. 4). In these cases release factors are not believed to compete with the tRNA for A-site binding, suggesting that the decreased functional interaction with RF1 cannot account for all the properties of ribo-X. We therefore looked for features within the tRNA structure which ribo-X might be optimized to recognize.

The extended anticodon tRNAs used in this study have purines at position 32 in the anticodon loop and phylogenetically unusual combinations of nucleotides at positions 32 and 38. Uhlenbeck and coworkers have shown, in the context of triplet decoding, that natural variation in the identity of the 32-38 pair can influence the affinity of tRNAs for the ribosomal A-site. The A-site of ribo-X may have optimized affinity for expanded anticodon tRNAs with unusual nucleotides at position 32 and 38 while maintaining close to optimal affinity for natural tRNAs. Consistent with this view, we find that conversion of the 32-38 pair in the AGGA tRNA from A32C38 to C32A38, as found in tRNA−− produces an extended anticodon tRNA read equally poorly by the progenitor O-ribosomes and by ribo-X (Fig. 4).

We have demonstrated the first example of synthetic evolution of ribosome function in living cells. We have shown that orthogonal ribosomes can be evolved to more efficiently decode a range of extended codons using tRNAs with extended anticodon loops. The evolved orthogonal ribosome, ribo-X, preferentially reads quadruplet codons with extended anticodon tRNAs and can show specificity for Watson-Crick base pairs at the fourth position of the codon-anticodon interaction. Ribo-X also improves amber suppression by amber suppressor tRNAs. Finally we have provided experimental support for a model which explains the mode of action of ribo-X, and implicates the 530 loop, in the ribosome decoding centre, in functional interactions with RF1.

The observation that ribo-X can improve the efficiency with which full length proteins are synthesized from orthogonal mRNAs containing amber codons has technological significance. Almost all current methods of introducing unnatural amino acids into proteins in vivo rely on amber suppression, and produce a large fraction of truncated protein, as a result of release factor mediated peptide chain termination. Release factor mediated protein truncation reduces protein yield and, for in vivo studies using unnatural amino acids to probe cellular function, truncated proteins can have unforeseen functional and phenotypic effects that perturb precisely the system under investigation. Ribo-X should facilitate in vivo studies with unnatural amino acids and may also allow improvements in total protein yield for expression systems that exploit incorporation of unnatural amino acids in response to the amber codon. Importantly since ribo-X’s primary mode of action on UAG codons is decreasing release factor binding it will exert its enhancement of UAG decoding for the wide range of amber suppressor tRNAs used for unnatural amino acid incorporation in E. coli.

By improving the quadruplet decoding of the orthogonal ribosome we have diverged the decoding properties of the orthogonal ribosome from those of the cellular ribosome such that the same insertion signal is read with a different efficiency on cellular and orthogonal mRNAs within the same cell. Since the meaning of codons on any mRNA is set by the translational machinery that decodes that mRNA, it may be possible to use extensions of our approach to bypass the “frozen accident” of the existing genetic code and write quadruplet codons or other genetic codes on orthogonal mRNAs, using tRNAs that are poor substrates for the cellular ribosome but are efficiently decoded by evolved orthogonal ribosomes. Such parallel and independent codes (orthogonal genetic codes) would expand the information storage capacity of the cell and might be used to extend in vitro computation to living cells. Moreover orthogonal codes might be used to encode the biosynthesis of unnatural polymers and to create insululated genetic codes for encoding the components of synthetic genetic circuits in a form unreadable by, and therefore not functionally transmissible to, natural biological entities.

Example 3

Evolved Orthogonal Ribosomes with Enhanced Efficiency

Design of a Ribosome Decoding Centre Library

The A-site of the ribosome is the gateway to the tRNA translocation corridor composed of the A, P and E sites. In response to an amber codon in the A-site of the ribosome RF-1 can bind to the A-site and compete with decoding of amber suppressor tRNAs. We reasoned that combinations of mutations in 16S rRNA, which forms the A-site of the ribosome, might yield a variant A-site that allows amber suppressor tRNAs to compete more effectively with RF-1 for A-site binding, and thus favour amber suppression and elongation over polypeptide chain termination.

To design an A-site library (Fig. 8) we examined the structures of tRNAs or RF-1 bound to the ribosomal A-site. These structures show that the 530 loop in 16S rRNA is proximal to both substrates (Fig. 8). We reasoned that combinations of mutations in the 530 loop might maintain tRNA binding, but decrease functional interaction with RF-1 in the presence of a UAG codon. We therefore randomized seven nucleotides (529-535) in the 530 loop to all combinations of nucleotides to create an N7 library. Moreover, we created longer and shorter 530 loop sequence libraries (N5, N6, N8, and N9 (Fig. 8)) to expand the functional space sampled. All libraries were more than 99% complete (Supplementary Table 1).

Selection of Evolved Decoding in Orthogonal Ribosomes

To create a selection system for orthogonal ribosomes that more efficiently read amber codons, we required a reporter of orthogonal ribosome activity that contains selector codons. We decided to work initially with a UAGA containing reporter and tRNA−− (UCUA) (Fig. 14), which is aminoacylated by seryl-tRNA synthetase, rather than a simple UAG suppressor, because it allows selection for improved ribosome activity over a larger dynamic range. Cells containing O-cot (UAGA103, UAGA146)/tRNA−− (UCUA) and the O-ribosome had an IC50 on chloramphenicol of 25 μg mL−1. For comparison, the O-cot reporter devoid of UAGA codons supports growth on 500 μg mL−1 of chloramphenicol in the presence of the O-ribosome.

To select mutant ribosomes that more efficiently decode the UAGA codon we combined each orthogonal ribosome
library with O-cat (UAGA103, UAGA146)/tRNA^{\text{ser}} (UCU) (in which cat containing UAGA codons is translated from an orthogonal ribosome binding site, FIG. 15) and challenged the cells to grow on chloramphenicol concentrations at which the O-ribosome does not support growth. No clones containing insertions or deletions survived for libraries N5, N6, N8 and N9, suggesting that the 530 loop is intolerant to longer or shorter sequences of any composition. However, clones from the N7 library did survive on 100 μg ml^{-1} chloramphenicol. All ten clones sequenced from the N7 selection were identical, and contained the mutations U531G and U534A in 16S rRNA (FIG. 9). The U531G mutation is present in only two sequenced vertebrate mitochondrial rRNAs while the U534A mutation is present in 0.2% of bacterial rRNAs. No sequenced natural ribosome contains this combination of mutations\(^24\). Because it remained a formal possibility that more efficient ribosomes for UAG decoding existed in the libraries but were not captured by the UAG selection we repeated the selection with reporters containing the UAG codon and an amber suppressor derived from tRNA^{\text{ser}} (FIG. 14). We found that the same sequence was uniquely selected. We therefore decided to characterize the U531G, U534A mutant ribosome, which we refer to as ribo-X, in more detail.

Ribo-X Enhances tRNA Dependent UAGA Decoding

To measure the extent to which ribo-X enhances tRNA^{\text{ser}} (UCU) dependent decoding of the UAGA codon, we compared the chloramphenicol resistance of cells containing O-cat (UAGA103, UAGA146)/tRNA^{\text{ser}} (UCU) and either ribo-X or the progenitor O-ribosome (FIG. 9). Ribo-X containing cells survive on concentrations of chloramphenicol five times higher than cells containing the progenitor O-ribosome. The enhanced, tRNA^{\text{ser}} (UCU) dependent, quadruplet decoding was further confirmed by in vitro chloramphenicol acetyl transferase (CAT) assays\(^{25}\) (FIG. 9). Similar ribo-X mediated enhancements were observed using tRNA^{\text{ser}} (CUA) and a cognate O-cat reporter. The chloramphenicol resistance conferred on cells by ribo-X and O-cat and the progenitor O-ribosome and O-cat is identical (500 μg ml^{-1}), indicating that ribo-X is efficient and processive in translation of sense codons.

Ribo-X and Natural Ribosomes have Comparable Fidelity

To demonstrate that ribo-X synthesizes proteins with a fidelity comparable to the natural ribosome, we compared the mass spectra, and amino acid mis-incorporation frequency of proteins synthesized by wild-type ribosomes, the progenitor orthogonal ribosome and ribo-X.

Expression of O-gst-malE (a genetic fusion between the genes encoding glutathione-S-transferase (GST) and maltose binding protein (MBP) driven by an orthogonal ribosome binding site) in the presence of ribo-X or the progenitor O-ribosome produced GST-MBP with a purified yield of 30-40 mg 1^{-1}, comparable to the yield of GST-MBP produced from a gst-malE fusion by wild-type ribosomes. As expected, no GST-MBP can be purified from O-gst-malE in the absence of orthogonal ribosomes (FIG. 10a). Thrombin cleavage of GST-MBP, at a site between GST and MBP in the protein fusion (FIG. 16), produced two proteins that were amenable to mass determination by electrospray ionization mass-spectrometry. Proteins produced from each ribosome had the same mass (FIG. 10b). To explicitly compare the translational fidelity of ribo-X to that of progenitor ribosomes, we measured the frequency of \(^{35}\)S-cysteine mis-incorporation\(^26\) into MBP, which contains no cysteine codons (FIG. 10c). The error frequency per codon translated by ribo-X was less than 1×10^{-5}. Control experiments with the progenitor orthogonal ribosome and the wild-type ribosome allowed us to put the same limit on their error frequency. This limit compares well with a previous measurement for amino acid mis-incorporation frequency, as measured by \(^{35}\)S-cysteine mis-incorporation\(^26\), of 4×10^{-5} errors per codon. To further probe the translational fidelity of ribo-X with respect to defined perturbations in the codon-anticodon interaction, we took advantage of a dual luciferase reporter system (DLR) that has previously been used to measure the fidelity of natural and error-prone ribosomes in decoding near-cognate and non-cognate codons\(^37\). We created a DLR with an orthogonal ribosome-binding site (O-DLR), and demonstrated that its translation is dependent on the presence of a cognate orthogonal ribosome (FIG. 17). We translated O-DLR variants, for which K529(AAA) was mutated at each position of the codon-anticodon interaction (FIG. 10a), using ribo-X or the progenitor orthogonal ribosome, and compared the resulting luciferase activities as a measure of translational mis-reading. We find that the fidelity of ribo-X is at least as good as that measured for the progenitor orthogonal ribosome and the natural ribosome across all four codon-anticodon interactions tested.

Overall, the mass spectra, \(^{35}\)S mis-incorporation assay and dual luciferase assays demonstrate that ribo-X has a translational fidelity comparable to that of the natural ribosome.

Increased Efficiency Unnatural Amino Acid Incorporation

To demonstrate the substantial increase in efficiency of site-specific unnatural amino acid incorporation with ribo-X, we chose to work with the photocrosslinking amino acid p-benzoyl-L-phenylalanine (Bpa)\(^28\). This amino acid has been added to the genetic code of E. coli, yeast and mammalian cells and used extensively to map the topology of protein-protein interactions in vitro and in vivo\(^5, 20, 30-42\). We expressed gst(UAG)malE in the presence of a p-benzoyl-L-phenylalanyl-RNA synthetase/tRNA^{\text{Clu}} pair\(^{29}\) (evolved from the MJtYrrS/tRNA^{\text{Clu}} pair). Bpa and wild-type ribosomes (FIG. 11a). As expected, this produced GST-MBP, incorporating Bpa, with low efficiency (24%). However when we synthesized GST-MBP containing Bpa from O-gst(UAG)malE using the BpaRS/tRNA^{\text{Clu}} pair, Bpa and ribo-X, the efficiency increased to 62%. As expected, based on the previously reported specificity of BpaRS, full-length protein synthesis is Bpa dependent\(^30\). In our experiments, performed in Luria Bertani (LB) medium as previously described\(^23\), we see a small amount of full-length protein synthesis that is BpaRS and tRNA^{\text{Clu}} dependent, but not amino acid dependent (compare FIG. 11a, lanes 2 and 6 and 10). This effect is minimized in minimal medium, where the total yields of overexpressed proteins are also approximately five times lower (FIG. 18). In the presence of Bpa, the aminocyclation of natural amino acids onto tRNA^{\text{Clu}} by non-cognate aminocycl-RNA synthetases observed in rich media is out-competed, and incorporation of Bpa is quantitative\(^23\) (FIG. 11a, c, d). Mass spectrometry shows that BpaRS expression from pStuP3Bpa does not lead to detectable levels of unnatural amino acid incorporation in response to sense codons (via misacylation of endogenous tRNAs), as expected from the observation that MJtYrrS does not aminocyclate any E. coli tRNAs with tyrosine, even in the absence of competing endogenous aminoacyl-RNA synthetase enzymes\(^32\). In the absence of a functional aminocycl-RNA synthetase/tRNA^{\text{Clu}} pair, ribo-X terminates translation on the amber codon, and no full-length GST-MBP fusion is purified (FIG. 11a, lane 10). Similarly, ribo-X does not measurably enhance read-through of a UAA or UGA codons.

The ribo-X mediated enhancement of efficiency was even more dramatic for a gene containing two amber stop codons (FIG. 11a): wild-type ribosomes produced GST-MBP con-
containing two Bpas from gst(UAG)malE with an efficiency of less than 1%, while ribo-X produced GST-MBP containing two Bpas with an efficiency at least twenty-fold higher (22%) from O-gst(UAG)malE. Extrapolation of the single UAG efficiencies to two sites predicts efficiencies of 38% and 6% for ribo-X and the wild-type ribosome respectively. Comparison of the ratio of predicted to observed efficiencies for each ribosome suggests that ribo-X may be more robust than the wild-type ribosome to context effects which decrease the efficiency of UAG suppression. Electrospray ionization mass spectrometry of MBP produced by ribo-X in the presence of the BpaRS/tRNA<sub>Glu</sub> pair and Bpa confirmed the incorporation of 2 Bpas; no peaks were detected corresponding to the incorporation of natural amino acids (Fig. 11b). The sites of Bpa incorporation were further confirmed by analysis of the MS/MS fragmentation series of the relevant chymotryptic peptides (Figs. 11c & 11d). We observe that the ribo-X mediated improvement in efficiency for one and two amber codons is conserved in minimal medium (Fig. 18), demonstrating that the effect mediated by ribo-X is robust under different expression conditions. Overall, the protein expression data and mass spectrometry data clearly demonstrate that the modular combination of ribo-X, BpaRS/tRNA<sub>Glu</sub> and an orthogonal tRNA containing multiple UAG codons allows the site-specific incorporation of Bpa with high fidelity and efficiency at multiple sites in GST-MBP.

Materials and Methods to Example 3: Construction of Ribosome Libraries and Reporters

16S rDNA libraries were constructed by enzymatic inverse PCR<sup>1</sup> on pRSF vectors containing a previously described O-rDNA (pRSF-O-rDNA)<sup>1</sup>. To create the UAGA reporter plasmid we introduced the amber derived UAGA codon at two sites in the chloramphenicol acetyl transferase (cat) gene (Ser103 and Ser146, an essential and conserved catalytic serine residue<sup>2</sup>that ensures the fidelity of incorporation, Fig. 15), downstream of an orthogonal ribosome-binding site, producing O-cat (UAGA103, UAGA146). This construct was created by multiple rounds of Quik Change mutagenesis (Stratagene) on an O-cat reporter derived from p21<sup>25</sup> by replacement of the cat-upt fusion with the cat gene alone. tRNA genes were introduced into the O-cat (UAGA103, UAGA146) plasmid at a unique BstZ171 restriction site, via a cassette containing a 5' synthetic lpp promoter and a 3' rmC transcriptional terminator, to create the vector O-cat (UAGA103, UAGA146)/tRNA(UCA); the sequence of the extended anticodon is written 5' to 3'. UAGA codon reporters and CUA anticodon tRNAs were derived by Quik Change mutagenesis from the UAGA or UCAU constructs. All final plasmids were confirmed by DNA sequencing. For a complete description of oligonucleotides used for vector construction see Supplementary Table 2.

Selection of Evolved O-Ribosomes

To select O-ribosomes with improved UAGA decoding, each pRSF-O-rDNA library was transformed by electroporation into GeneHog <i>E. coli</i> (Invitrogen) containing O-cat (UAGA103, UAGA146)/tRNA(UCA). Transformed cells were recovered for 1 h in S0B medium containing 2% glucose and used to inoculate 200 ml of LB-GKT (LB medium with 2% glucose, 25 μg ml<sup>-1</sup> kanamycin and 12.5 μg ml<sup>-1</sup> tetracycline). After overnight growth (37°C, 250 r.p.m., 16 h), 2 ml of the cells were pelleted by centrifugation (3000 g), and washed three times with an equal volume of LB-KT (LB medium with 12.5 μg ml<sup>-1</sup> kanamycin and 6.25 μg ml<sup>-1</sup> tetracycline). The resuspended pellet was used to inoculate 18 ml of LB-KT, and the resulting culture incubated (37°C, 250 r.p.m. shaking, 90 min). To induce expression of plasmid encoded O-rRNA, 2 ml of the culture was added to 18 ml LB-IKT (LB medium with 1.1 mM isopropyl-D-thiogalacto-pyranoside (IPTG), 12.5 μg ml<sup>-1</sup> kanamycin and 6.25 μg ml<sup>-1</sup> tetracycline) and incubated for 4 h (37°C, 250 r.p.m.). Aliquots (250 μl optical density at 600 nm (OD<sub>600</sub>)<sub>1.5</sub>) were plated on LB-IKT agar (LB agar with 1 mM IPTG, 12.5 μg ml<sup>-1</sup> kanamycin and 6.25 μg ml<sup>-1</sup> tetracycline) supplemented with 50 μg ml<sup>-1</sup> chloramphenicol and incubated (37°C, 40 h).

Characterization of Evolved O-Ribosomes

To separate selected pRSF-O-rDNA plasmids from the O-cat (UAGA103, UAGA146)/tRNA<sup>UCA</sup> (UCAU) reporter plasmids, total plasmid DNA from selected clones was purified and digested with Not I restriction endonuclease, and transformed into DH10B <i>E. coli</i> cells. Individual transformants were replica plated onto kanamycin agar and tetracycline agar and plasmid separation of pRSF-O-rDNA from the reporter confirmed by restriction digest and agarose gel analysis. To quantify the UAGA decoding activity of selected 16S rDNA clones, selected pRSF-O-rDNA plasmids were co-transformed with O-cat (UAGA103, UAGA146) or O-cat (UAGA103, UAGA146)/tRNA<sup>UCA</sup> (UCAU). Cells were recovered (SOB, 2% glucose, 1 h) and used to inoculate 10 ml of LB-GKT, which was incubated (16 h, 37°C, 250 r.p.m.). 1 ml of the resulting culture was used to inoculate 9 ml of LB-KT, which was incubated (90 min, 37°C, 250 r.p.m.). 1 ml of the LB-KT culture was used to inoculate 9 ml of LB-IKT medium, which was incubated (37°C, 250 r.p.m., 4 h). Individual clones were transferred to a 96-well block and arrayed, using a 96 well pin tool, onto LB-IKT agar plates containing chloramphenicol at concentrations from 0 to 250 μg ml<sup>-1</sup>. The plates were incubated (37°C, 16 h). We performed analogous experiments for other RNA codon pairs.

To extract soluble cell lysates for in vitro CAT assays, 1 ml of each induced LB-IKT culture was pelleted by centrifugation at 3,000 g. The cell pellets were washed three times with 500 μl Washing Buffer (40 mM Tris-HCl, 150 mM NaCl, 1 mM EDTA, pH 7.5) and once with 500 μl Lysis Buffer (250 mM Tris-HCl, pH 7.8). Cells were lysed in 200 μl Lysis Buffer by five cycles of flash-freezing in dry-ice/ethanol followed by rapid thawing in a 50°C water-bath. Cell debris was removed from the lysate by centrifugation (12,000 g, 5 min) and the top 150 μl of supernatant frozen at −20°C. To assay CAT activity in the lysates, 10 μl of soluble cell extract was mixed with 2.5 μl of FAST CAT Green (deoxy) substrate (Invitrogen) and pre-incubated (37°C, 5 min). 2.5 μl of 19 mM acetyl-CoA (Sigma) was added, and the reaction incubated (37°C, 1 h). The reaction was stopped by the addition of ice-cold ethyl acetate (200 μl, vortex 20 s). The aqueous and organic phases were separated by centrifugation (12,000 g, 10 min) and the top 100 μl of the ethyl acetate layer collected. 1 μl of the collected solution was spotted onto a silica gel TLC plate (Merck) for thin-layer chromatography in chloroform:methanol (85:15 v/v). The fluorescence of the spatially resolved substrate and product was visualized and quantified using a phosphorimager (Storm 860, Amersham Biosciences) with excitation and emission wavelengths of 450 nm and 520 nm, respectively.

Construction of GST-MBP Protein Expression Vectors

GST was amplified from pGEX-2T (GE Healthcare) with the primes:

1. GAACCTGAGACACACTTTTATCATCCTCTTCGGAATGTCCTCCATACGTTAGGTTAGAAAT
   (SEQ ID NO:1) and GAGAAGTACCCGTCTCTCGATATAACCGCTACCCAGGGAAC
   (SEQ ID NO:2), and digested with Xho I and Kpn I. Full-length was
   amplified from pMAL (NEB) with PCR primes GAAGGTACCTCAGAAATCGGAAAGGAAGTAACTGTAATC
   (SEQ ID
Expression and Purification of GST-MBP Fusions

E. coli containing the appropriate plasmid combinations were pelleted (3000 g, 10 min) from 50% ammonium
resuspended in 1 ml Lysis buffer (Phosphate buffered saline (PBS) supplemented with 1x protease
inhibitor cocktail (Roche), 1 mM PMSF and 1 mg/ml lysisome (Sigma)), and incubated (15 min, 37° C, 1000
rpm). Cells were chilled on ice before lysis by sonication (30 s, 30 W). The lysate was clarified by
centrifugation (6 min, 25000 g, 2 °C). GST containing proteins from the lysate (875 µg, 400 µl) were
bound in batch (1 h, 4 °C) to 50 µl of Glutathione sepharose beads (GE Healthcare). Beads were washed 3
times with 1 ml PBS, before elution by heating for 10 min at 80 °C in 60 µl 1x SDS gel-loading buffer. All samples
were analysed on 4-20% Tris-Glycine gels (Invitrogen).

The densities of the bands for GST-MBP and GST were quantified from Coomasie stained gels with NIH image
image. We divided the background-corrected values by the molecular mass of the corresponding proteins (GST-MBP, 71 kDa
and GST, 27 kDa) and used these values to calculate the percentage of amber codon suppression, by
dividing the amount of GST-MBP by total amount of protein.

35S-Cysteine Mis- Incorporation

or pgst-malE were resuspended in LB media (supplemented with
35S-cysteine (1000 Ci mmol-1) to a final concentration of
3 nM, 750 µM methionine, 25 µg ml-1 ampicillin and 12.5
µg ml-1 kanamycin) to an OD600 of 0.1, and cells were
incubated (3.5 h, 37°C, 250 rpm). The resulting culture was
pelleted (5000 g, 5 min), washed twice (1 ml PBS per wash),
resuspended in 1 ml PBS containing 1% Triton-X, and
lysed on ice by pipetting up and down. The clarified cell
extract was bound to 100 µl of glutathione sepharose beads
(1 h, 4°C) and the beads were pelleted (5000 g, 10 s) and
washed twice in 1 ml PBS. The beads were added to 10 ml
destilled water (Biorad) and washed (30 ml of PBS;
10 ml 0.5M NaCl, 0.5xPBS; 30 ml PBS) before elution in 1
ml of PBS supplemented with 10 mM glutathione. Purified
GST-MBP was digested with 12.5 units of thrombin, to yield
a GST fragment and an MBP fragment. The reaction was
loaded onto an SDS-PAGE gel to resolve the GST, MBP
and thrombin, and stained with GelCode blue (Invitrogen).
The 35S activity in the GST and MBP protein bands were
quantified by densitometry, using a Storm Phosphoimager
(Molecular Dynamics) and ImageQuant (GE Healthcare) and by
scintillation counting of excised bands. The error frequency per
codon for each ribosome examined was determined as follows:
GST contains 4 cysteine codons, so the number of
counts per second (cps) resulting from GST divided by four
gives A, the cps per quantitative incorporation of cysteine.
MBP contains no cysteine codons, but mis-incorporation
at non-cysteine codons gives B cps. Since GST and MBP are
present in equimolar amounts, (A/B)=410, where 410 is the
number of amino acids, in the MBP containing thrombin
cleavage fragment, gives the number of amino acids trans-
lated for one cysteine mis-incorporation. C is the
amino acid suppression frequency and the number of
counts transduced per mis-incorporation is C/20.

Dual Luciferase Assays

pO- DLR contains a genetic fusion between a 5′ Renilla
Luciferase (R-luc) and a 3′ Firefly Luciferase (F-luc) on
an orthogonal ribosome binding site. To create pO-DLR the
R-luc open reading frame from the plasmid pGL4.70[hRluc]
(Promega) was amplified by PCR using the primers
GAACCTCAAGGGCGCTGTCGATCTCCTTATCATCATCCCTCGCAATG
CACATCCGTCAGAATGACGTTCTACCGAAGAATGACGTTCTAC
CACCGACCCAGCAAGCGAAAGCCAT(G (SEQ ID NO:13) and
GCTAGATCTCAGCCGCTGGCGTCCCTTATCATCATCCCTCGCAATG
CACATCCGTCAGAATGACGTTCTACCGAAGAATGACGTTCTAC
CACCGACCCAGCAAGCGAAAGCCAT(G (SEQ ID NO:14). The PCR product was
digested with Xho I and Bgl II. The F-luc ORF was amplified
with primer pair AGGAGATCTCAAGGGCGCTGTCGATCTCCTTATCATCATCCCTCGCAATG
CACATCCGTCAGAATGACGTTCTACCGAAGAATGACGTTCTAC
CACCGACCCAGCAAGCGAAAGCCAT(G (SEQ ID NO:15) and GACAAAGCTTA
CACCGACCCAGCAAGCGAAAGCCAT(G (SEQ ID NO:13) and
GCTAGATCTCAGCCGCTGGCGTCCCTTATCATCATCCCTCGCAATG
CACATCCGTCAGAATGACGTTCTACCGAAGAATGACGTTCTAC
CACCGACCCAGCAAGCGAAAGCCAT(G (SEQ ID NO:14). The PCR product was
digested with Bgl II and Hind III. The GST-malE gene fusion
was excised from pO-gst-malE by Xho I and Hind III
digestion and pO-DLR created by a triple ligation of the
released vector backbone with the digested F-luc PCR product
and the digested R-luc PCR product. pwt-DLR was created
by a similar strategy, but using the primer pair GAACTC
GAACCTCAAGGGCGCTGTCGATCTCCTTATCATCATCCCTCGCAATG
CACATCCGTCAGAATGACGTTCTACCGAAGAATGACGTTCTAC
CACCGACCCAGCAAGCGAAAGCCAT(G (SEQ ID NO:13) and
GCTAGATCTCAGCCGCTGGCGTCCCTTATCATCATCCCTCGCAATG
CACATCCGTCAGAATGACGTTCTACCGAAGAATGACGTTCTAC
CACCGACCCAGCAAGCGAAAGCCAT(G (SEQ ID NO:14).
CATG SEQ ID NO:17) and GCTAGATCTCCTAGGGGC
CCGCCGTCAGATTGCTGTCGTCGGC
CAGGGCTCTACAAAGGCTC (SEQ ID NO:18) to amplify the R-luc ORF. Codon 529 variants were created by Quik Change Mutagenesis (Strategene).

pOE-DR, and its K529 codon variants, were transformed into GeneNlog E. coli cells with pSC101-O-rhodose or pSC101*-rbo-X, pwd-Dr, and its K529 codon variants, were transformed into GeneNlog cells with pSC101*-BD. Individual colonies were incubated (37°C, 250 rpm, 20 h) in 2 mL LB supplemented with ampicillin (100 mg mL⁻¹) and kanamycin (50 μg mL⁻¹), pelleted (5000 g, 5 min) and resuspended in 200 μL (1 mg mL⁻¹ lysozyme, 10 mM Tris (pH 8.0), 1 mM EDTA). Cells were incubated on ice for 20 min, frozen on dry ice, and thawed on ice. 10 μL samples of this extract were assayed for firefly (F-luc) and Renilla (R-luc) luciferase activity using the Dual-Luciferase Reporter Assay System (Promega). Each ribosome reporter combination was assayed from four independent cultures using an Orion microplate luminometer (Berthold Detection Systems) and the data analyzed as previously described. The report of the standard deviation.

Mass Spectrometry

25 μM GST-2BP-MBP (GST-MBP with Bpas incorporated in response to two amber codons) in 22 μL 40 mM (NH₄)HCO₃, was alkylated and digested with chymotrypsin overnight. To obtain a fragment series for the N-terminal Bpa incorporation, 5 μL of a tenfold dilution of the chymotryptic peptide mixture was desalted and concentrated by using a GE-Loader tip filled with Poros R3 sorbent (PepSepive Biosystems). The bound peptides were eluted with 1 μL of 40% acetonitrile/4% formic acid directly into a nanospray capillary and then introduced into an API QSTAR pulsar i hybrid quadrupole-time-of-flight mass spectrometer (MDS Sciex). Product ion scans were carried out in positive ion-mode and MS survey scans for peptides measured. Selected ions (n/z=669.445) were fragmented by collision-induced disso-


21. Short, G. F., 3rd, Golovine, S. Y. & Hecht, S. M. Effects of release factor 1 on in vitro protein translation and the
51. All patents, patent applications, and published references cited herein are hereby incorporated by reference in their entirety. While this invention has been particularly shown and described with references to preferred embodiments thereof, it will be understood by those skilled in the art that various changes in form and details may be made therein without departing from the scope of the invention encompassed by the appended claims.

REFERENCES

8. Magliery, T. J., Anderson, J. C. & Schultz, P. G. Expanding the genetic code: selection of efficient suppressors of four-


US 8,497,231 B2

SEQUENCE LISTING

<160> NUMBER OF SEQ ID NOS: 68

<210> SEQ ID NO 1
<211> LENGTH: 65
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: primer

<400> SEQUENCE: 1

gaaagttcga caatttccat atcctccgc aatgtcccc tatactaggt tatggaaaa 60
ttaag

<210> SEQ ID NO 2
<211> LENGTH: 45
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: primer

<400> SEQUENCE: 2

gaaaggtacc cgctagcag ataacctcgg gatccagcgg gsaac

<210> SEQ ID NO 3
<211> LENGTH: 39
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: PRIMER/RNA

<400> SEQUENCE: 3

gaaaggtacc taacaatcga aagaagtcga otggtaac

<210> SEQ ID NO 4
<211> LENGTH: 30
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: PRIMER/RNA

<400> SEQUENCE: 4

ccaaagttact ggtcgcttc gcagtcgactc

<210> SEQ ID NO 5
<211> LENGTH: 72
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: PRIMER/RNA

<400> SEQUENCE: 5

gtaggtctcg gatcccgagg tacctagaat taagagggag aatttaagca tgtcccttat 60
actaggatat tg

<210> SEQ ID NO 6
<211> LENGTH: 76
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: PRIMER/RNA

<400> SEQUENCE: 6

gtaggtctcg gatccctctag agtcgaacctg cgggaatgca aagctggggt aactcgcagcc
<210> SEQ ID NO: 7
<211> LENGTH: 52
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<222> OTHER INFORMATION: PRIMER/RNA

<400> SEQUENCE: 7
gaattcatcg tgtacggtag ctcaaatcg agaaggtaa acgtgtaatc tg

<210> SEQ ID NO: 8
<211> LENGTH: 52
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<222> OTHER INFORMATION: PRIMER/RNA

<400> SEQUENCE: 8
cctcagtttt gagctacccg tcaagtgaa attccgggga tccacggga ac

<210> SEQ ID NO: 9
<211> LENGTH: 49
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<222> OTHER INFORMATION: PRIMER/RNA

<400> SEQUENCE: 9
cctcaaatct agaaggtaa acgtgtaatc tggattaacg gccgataag

<210> SEQ ID NO: 10
<211> LENGTH: 39
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<222> OTHER INFORMATION: PRIMER/RNA

<400> SEQUENCE: 10
cagtttacct cctagattt tgtaccccg gtcacgtg

<210> SEQ ID NO: 11
<211> LENGTH: 31
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<222> OTHER INFORMATION: PRIMER/RNA

<400> SEQUENCE: 11
actcgatcct gtsagagga tcaaataaa c

<210> SEQ ID NO: 12
<211> LENGTH: 29
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<222> OTHER INFORMATION: PRIMER/RNA

<400> SEQUENCE: 12
agttcaggttt gacggtcggga attgccagc

<210> SEQ ID NO: 13
<211> LENGTH: 77
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: PRIMER/RNA

<400> SEQUENCE: 13

gaacctgagg gcgggtcctt catatcctc cgcaaatggc ctccaaqggg taccgacccag 60
agcaacgcaaa agcagt

<210> SEQ ID NO 14
<211> LENGTH: 64
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: PRIMER/RNA

<400> SEQUENCE: 14

gctagatcct ctacgggccc ccgctcagat ttgctgtcct ttccacaagc gctcccacgaa 60
gctc

<210> SEQ ID NO 15
<211> LENGTH: 67
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: PRIMER/RNA

<400> SEQUENCE: 15

agggactatca gcgtccgagct ccccgaggag atccatcgaat ccacctgagagg 60
gccgcag

<210> SEQ ID NO 16
<211> LENGTH: 35
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: PRIMER/RNA

<400> SEQUENCE: 16

gacaagcttt caacgcgcat ctgcctgctc ttctg 35

<210> SEQ ID NO 17
<211> LENGTH: 80
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: PRIMER/RNA

<400> SEQUENCE: 17

gaacctgagtacctagatat aagaggaga aattagcat gcctcctcaag gttctacgcc 60
ccgtacagcga ccacgcctatg

<210> SEQ ID NO 18
<211> LENGTH: 64
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: PRIMER/RNA

<400> SEQUENCE: 18

gctagatcct ctacgggccc ccgctcagat ttgctgtcct ttccacaagc gctcccacgaa 60
gctc

<210> SEQ ID NO 19
<211> LENGTH: 21
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: PRIMER/RNA

<400> SEQUENCE: 19

gctagatcct ctacgggccc ccgctcagat ttgctgtcct ttccacaagc gctcccacgaa 60
gctc
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthesized

SEQUENCE: 19
agcagcgcg guauacgga g

SEQ ID NO 20
LENGTH: 21
TYPE: RNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthesized
NAME/KEY: misc_feature
LOCATION: (10)...(16)
OTHER INFORMATION: n is a, c, g, or u

SEQUENCE: 20
agcagcgcg nnnnncggga g

SEQ ID NO 21
LENGTH: 19
TYPE: RNA
ORGANISM: Artificial
FEATURE:
OTHER INFORMATION: RNA
NAME/KEY: misc_feature
LOCATION: (10)...(14)
OTHER INFORMATION: n is a, c, g, or u

SEQUENCE: 21
agcagcgcg nnnncggag

SEQ ID NO 22
LENGTH: 20
TYPE: RNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: RNA
NAME/KEY: misc_feature
LOCATION: (10)...(15)
OTHER INFORMATION: n is a, c, g, or u

SEQUENCE: 22
agcagcgcg nnnncgcggag

SEQ ID NO 23
LENGTH: 22
TYPE: RNA
ORGANISM: Artificial
FEATURE:
OTHER INFORMATION: Synthesized
NAME/KEY: misc_feature
LOCATION: (10)...(17)
OTHER INFORMATION: n is a, c, g, or u

SEQUENCE: 23
agcagcgcg nnnnncggag

SEQ ID NO 24
LENGTH: 23
TYPE: RNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthesized


<221> NAME/KEY: misc_feature
<222> LOCATION: (10) ...(18)
<223> OTHER INFORMATION: n is a, c, g, or u

<400> SEQUENCE: 24
agcagccgon nnnnnnncg gag

<210> SEQ ID NO 25
<211> LENGTH: 15
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: Synthesized

<400> SEQUENCE: 25
acgttttcat cgctc

<210> SEQ ID NO 26
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthesized

<400> SEQUENCE: 26
acgttttmmn tgcctc

<210> SEQ ID NO 27
<211> LENGTH: 15
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: Synthesized

<400> SEQUENCE: 27
acgtttaga gtctc

<210> SEQ ID NO 28
<211> LENGTH: 15
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthesized

<400> SEQUENCE: 28
ttcgtctcag ccaat

<210> SEQ ID NO 29
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthesized

<400> SEQUENCE: 29
ttcgttmmn gcaat

<210> SEQ ID NO 30
<211> LENGTH: 5
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthesized

<400> SEQUENCE: 30

Thr Phe Ser Ser Leu

1 5

<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthesized

<400> SEQUENCE: 31

Thr Phe Xaa Ser Leu

1 5

<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthesized

<400> SEQUENCE: 32

Thr Phe Xaa Ser Leu

1 5

<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthesized

<400> SEQUENCE: 33

Phe Val Ser Ala Asn

1 5

<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthesized

<400> SEQUENCE: 34

Phe Val Xaa Ala Asn

1 5

<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthesized
<220> SEQUENCE: 35
<221> NAME/KEY: misc_feature
<222> LOCATION: (21)...(25)
<223> OTHER INFORMATION: n is a, c, g, or t

```
ggaaggtct cagcagcgc nnnnnccga ggtgcacgc ttaatcgga ttac
```

<210> SEQ ID NO 36
<211> LENGTH: 55
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (21)...(26)
<223> OTHER INFORMATION: n is a, c, g, or t

```
ggaaggtct cagcagcgc nnnnnccga ggtgcacgc gttaatcgg aattac
```

<210> SEQ ID NO 37
<211> LENGTH: 56
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (21)...(27)
<223> OTHER INFORMATION: n is a, c, g, or t

```
ggaaggtct cagcagcgc nnnnnccgg aggtgcacaag gtttaatcgg aattac
```

<210> SEQ ID NO 38
<211> LENGTH: 57
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (21)...(28)
<223> OTHER INFORMATION: n is a, c, g, or t

```
ggaaggtct cagcagcgc nnnnnncgg ggggtgcaag gtttaatcgg aattac
```

<210> SEQ ID NO 39
<211> LENGTH: 58
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (21)...(29)
<223> OTHER INFORMATION: n is a, c, g, or t

```
ggaaggtct cagcagcgc nnnnnnncc ggggtgcaag gtttaatcgg aattac
```

<210> SEQ ID NO 40
<211> LENGTH: 46
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthesized

```
ggaaggtct cagcagcgc nnnnnnnnc ggggtgcaag gtttaatc ggattac
```

<210> SEQ ID NO 41
<211> LENGTH: 45
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthesized
SEQ ID NO 41
LENGTH: 45
TYPE: DNA
ORGANISM: Artificial
FEATURE:
OTHER INFORMATION: Synthesized

SEQUENCE: 41

gagtaggtct caactggtgc acggagttag cccggtcatt tcctag 45

SEQ ID NO 42
LENGTH: 88
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthesized

SEQUENCE: 42

cacaagtata cgcctctttc ttagagcaac gataaaaaat aagtggtgcc ccatcaaaaa 60
aatatttcta acataaaaaa ctttgtgtaa tatttg 96

tgtagacgct cggagcgtc gaaaggac 88

tgcaaacatg taaaactcct tattactttg 60
ggcagagct cggagcgtc gaaaggac 88

SEQ ID NO 43
LENGTH: 91
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthesized

SEQUENCE: 43

gtgcggggag gaggggggatt tgaacccccg tgtagaggtgc cctactcagg tgttataatt 60
acccggctgc tcaacccgtc gggcactctc c 91

SEQ ID NO 44
LENGTH: 86
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthesized

SEQUENCE: 44

cacaagtata ctttttttaa atctctagct ttcgttacgg atctgcagcc cggggccggcc 60
tagtgccgg agagaggggg atttgaa 98

SEQ ID NO 45
LENGTH: 50
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthesized

SEQUENCE: 45

cagaacggaa cgttttagat cgcctggag tgaatcacc gacgaattccc 50
ttcactcag agcgactaaa acgttttcag tctgtcatg gaaaaacgtg

aatatgttta tgtcttagag ccaatccctg ggtgagtttc accagttttg

caccagggc tgggctctag acgaaaaaca ttttcta attccttta g

cagactgaaa cgttttagtc gctotggagt gaataccacg acgatttcc

ttcactcag agcgactaaa acgttttcag tctgtcatg gaaaaacgtg

aatatgttta tgtcttagag ccaatccctg ggtgagtttc accagttttg

caccagggc tgggctctag acgaaaaaca ttttcta attccttta g
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthesized

<400> SEQUENCE: 53
ctactcgggt gttagttatacggtcgtcgctac oggoctcgct acaaatca ctcaaatctaa caagaaggt

<210> SEQ ID NO 54
<211> LENGTH: 50
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthesized

<400> SEQUENCE: 54
tgaaogggc gttatactaa caacgggagta gggcacaactaconcggggt

<210> SEQ ID NO 55
<211> LENGTH: 15
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthesized

<400> SEQUENCE: 55
aegtttcat ggcgc

<210> SEQ ID NO 56
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthesized

<400> SEQUENCE: 56
aegtttucag ctcga

<210> SEQ ID NO 57
<211> LENGTH: 15
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthesized

<400> SEQUENCE: 57
ttctctcag ccaaat

<210> SEQ ID NO 58
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthesized

<400> SEQUENCE: 58
ttctctca gcaaat

<210> SEQ ID NO 59
<211> LENGTH: 72
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthesized

<400> SEQUENCE: 59
cgtgcgcc gcgggatccccc gggaattcagctgacggggt acclcaaat cggagaaggt
aaacgtgaaa tc

<210> SEQ ID NO 60
<211> LENGTH: 24
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthesized

<400> SEQUENCE: 60
Leu Val Pro Arg Gly Ser Pro Gly Ile His Arg Asp Gly Tyr Leu Lys
1 5 10 15
Ile Glu Glu Gly Lys Leu Val Ile
20

<210> SEQ ID NO 61
<211> LENGTH: 17
<212> TYPE: RNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthesized

<400> SEQUENCE: 61
cgcgcgaau aogsgag
17

<210> SEQ ID NO 62
<211> LENGTH: 17
<212> TYPE: RNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<222> LOCATION: (5) .. (11)
<223> OTHER INFORMATION: n is a, c, g, or u

<400> SEQUENCE: 62
cgcgmnmmn noggag
17

<210> SEQ ID NO 63
<211> LENGTH: 17
<212> TYPE: RNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthesized

<400> SEQUENCE: 63
cgcgcgggaas aoggag
17

<210> SEQ ID NO 64
<211> LENGTH: 17
<212> TYPE: RNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<222> LOCATION: (7) .. (7)
<223> OTHER INFORMATION: n is a, c, g, or u

<400> SEQUENCE: 64
cgcgcgnaaa aoggag
17

<210> SEQ ID NO 65
<211> LENGTH: 17
<212> TYPE: RNA
<213> ORGANISM: Artificial
The invention claimed is:
1. An evolved orthogonal ribosomal RNA (rRNA) which possesses an enhanced efficiency of rRNA-dependent reading of orthogonal mRNA codons, wherein said orthogonal rRNA is a 16S rRNA containing a mutated 530 loop such that the 16S rRNA comprises the sequence 529-GGGAAAA-535.
2. An evolved orthogonal rRNA according to claim 1, wherein the orthogonal mRNA codons are extended codons or stop codons.
3. An evolved orthogonal rRNA according to claim 2, wherein the orthogonal mRNA codon is a quadruplet codon or an amber stop codon.
4. An evolved orthogonal rRNA according to claim 1, which possesses a decreased functional interaction with release factor 1 (RF-1).
5. An orthogonal ribosome incorporating an evolved orthogonal rRNA according to claim 1.
6. A cell comprising two or more protein translation mechanisms, wherein:

   (a) a first mechanism is the natural translation mechanism wherein mRNA is translated by a ribosome in accordance with the natural genetic code; and
   (b) a second mechanism is an artificial mechanism, in which orthogonal mRNA comprising orthogonal codons is translated by an orthogonal ribosome; wherein the orthogonal codons in the orthogonal mRNA are (i) not translated by the natural ribosome, or (ii) translated more efficiently by the orthogonal ribosome than by the natural ribosome, or (iii) translated into different polypeptides by the orthogonal ribosome and the natural ribosome, and wherein the orthogonal ribosome incorporates an evolved orthogonal ribosomal RNA (rRNA) which possesses an enhanced efficiency of rRNA-dependent reading of orthogonal mRNA codons, wherein said orthogonal rRNA is a 16S rRNA containing a mutated 530 loop such that the 16S rRNA comprises the sequence 529-GGGAAAA-535.

* * * * *

The invention claimed is:
1. An evolved orthogonal ribosomal RNA (rRNA) which possesses an enhanced efficiency of rRNA-dependent reading of orthogonal mRNA codons, wherein said orthogonal rRNA is a 16S rRNA containing a mutated 530 loop such that the 16S rRNA comprises the sequence 529-GGGAAAA-535.
2. An evolved orthogonal rRNA according to claim 1, wherein the orthogonal mRNA codons are extended codons or stop codons.
3. An evolved orthogonal rRNA according to claim 2, wherein the orthogonal mRNA codon is a quadruplet codon or an amber stop codon.
4. An evolved orthogonal rRNA according to claim 1, which possesses a decreased functional interaction with release factor 1 (RF-1).
5. An orthogonal ribosome incorporating an evolved orthogonal rRNA according to claim 1.
6. A cell comprising two or more protein translation mechanisms, wherein:

   (a) a first mechanism is the natural translation mechanism wherein mRNA is translated by a ribosome in accordance with the natural genetic code; and
   (b) a second mechanism is an artificial mechanism, in which orthogonal mRNA comprising orthogonal codons is translated by an orthogonal ribosome; wherein the orthogonal codons in the orthogonal mRNA are (i) not translated by the natural ribosome, or (ii) translated more efficiently by the orthogonal ribosome than by the natural ribosome, or (iii) translated into different polypeptides by the orthogonal ribosome and the natural ribosome, and wherein the orthogonal ribosome incorporates an evolved orthogonal ribosomal RNA (rRNA) which possesses an enhanced efficiency of rRNA-dependent reading of orthogonal mRNA codons, wherein said orthogonal rRNA is a 16S rRNA containing a mutated 530 loop such that the 16S rRNA comprises the sequence 529-GGGAAAA-535.

* * * * *